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Le proteine con ancora  carbossi-terminale, chiamate tail-anchored (proteine TA), 
costituiscono una classe di proteine di membrana coinvolte in funzioni fisiologiche 
fondamentali, quali la regolazione della esocitosi e dell'apoptosi. Le proteine TA hanno in 
comune una particolare topologia, che consiste in un dominio citosolico amino-terminale 
ancorata al doppio strato fosfolipidico da un segmento idrofobico molto vicino all'estremità 
carbossi-terminale. A causa di questa particolare topologia, queste proteine sono indirizzate 
alla loro destinazione mediante meccanismi esclusivamente post-traduzionali. Una via di 
targeting importante è centrata sulla ATPasi TRC40/Get3; tuttavia, almeno in condizioni 
acellulari, alcune proteine TA possono inserirsi in membrana in modo indipendente da 
questa via, e possono addirittura inserirsi spontaneamente in doppi strati fosfolipidici privi 
di proteine, senza assistenza di chaperone. Un esempio conosciuto di una proteina TA a 
inserzione spontanea è dato dal citocromo  b5, una proteina coinvolta nel metabolismo di 
lipidi e xenobiotici. Sono conosciute due forme del citocromo b5, che in vivo si localizzano al 
Reticolo Endoplasmatico (b5-ER) oppure alla membrana esterna mitocondriale (b5-RR). Il 
problema affrontato nella mia tesi è di come sia raggiunta la specifica localizzazione in vivo 
delle due forme nonostante la loro promiscuità in vitro. Per studiare questo problema, ho 
messo a punto un sistema basato su cellule coltivate semi-intatte, che possono essere 
manipolate e analizzate con metodi biochimici e di microscopia. In presenza di citosol, sia 
b5-RR che b5-ER, aggiunti o come proteine ricombinanti oppure come prodotti tradotti in 
vitro erano consegnati fedelmente alla corretta destinazione. Invece, in assenza di citosol, 
ambedue si localizzavano ai mitocondri, a indicare che fattori citosolici sono richiesti per 
evitare la localizzazione sbagliata di b5-ER alla membrana esterna mitocondriale. Ho 
dimostrato anche che il targeting di b5-ER richiede energia, e che sia la via TRC40 che la via 
di targeting SND2 identificata recentemente sono coinvolte solamente in piccola parte. Per 
identificare altre vie, ho utilizzato una varietà di inibitori di basso peso molecolare, incluse 
molecole che inibiscono proteine heat shock e l'AAA-ATPasi p97. L'inibizione  di Hsc70 e 
Hsp90 non ha avuto effetto, mente la Eeyarestatin (ES I), un inibitore sia di p97 che di Sec61 
(il traslocone responsabile per la traslocazione co-traduzionale) ha ridotto efficaciamente 
l'inserzione di b5-ER ma non di un substrato (sinaptobrevina 2) della via TRC40. 
Analogamente, ho trovato che il silenziamento di Sec61 ha inibito l'inserzione di b5-ER ma 
non di sinaptobrevina 2, a suggerire che l'interferenza di ES I è legata alla sua azione sul 
traslocone. Anche quando le due vie Sec61 e TRC40 sono state silenziate assieme, una 
notevole proporzione di b5-ER ha raggiunto il reticolo endoplasmatico, a indicare l'esistenza 
di altre vie di inserzione che rimangono da identificare. I miei risultati indicano che la 
membrana esterna mitocondriale rappresenta la via default per le proteine TA e rivelano 
l'esistenza di molteplici vie di targeting al reticolo, vie che sono ridondanti ma specifiche per 
substrati diversi. 
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Tail-anchored (TA) proteins constitute a class of membrane proteins whose diverse 
members carry out basic functions in cell physiology, including regulation of exocytosis and 
of apoptosis. TA proteins share a particular topology, consisting in a cytosolically located N-
terminal domain anchored to the bilayer by a C-terminal hydrophobic stretch. Because of 
this particular topology, these proteins are targeted to their destination by unique post-
translational pathways. An important identified pathway is centred on the ATPase 
TRC40/Get3, however, at least under cell-free conditions, some TA proteins can access 
membranes independently from this pathway, and can even insert spontaneously into 
protein-free phospholipid bilayers without assistance from any chaperone. One example of 
a spontaneously inserting TA protein is cytochrome b5, a protein involved in lipid and drug 
metabolism. Two forms of cyt b5 are known, which in vivo target either the Endoplasmic 
Reticulum (b5-ER) or the mitochondrial outer membrane (b5-RR). The question addressed 
in my thesis is how in vivo specificity is attained in the face of in vitro promiscuity. To 
investigate this problem, I set up a system based on semi-intact cultured cells, which can be 
manipulated and analysed biochemically and by immunofluorescence. In the presence of 
cytosol, both b5-RR and b5-ER, added either as recombinant proteins or as in vitro translated 
products, were faithfully targeted to their correct destinations. In contrast, in the absence 
of cytosol, both forms targeted the mitochondria, indicating that cytosolic factors are 
required to avoid mislocalisation of b5-ER to the mitochondrial outer membrane. I further 
demonstrated that ER targeting is energy-dependent, and that both the TRC40 and the 
recently described SND2 pathways are minimally involved. To elucidate further pathways, I 
used a number of small molecule inhibitors, including ones that target heat shock proteins 
and the AAA-ATPase p97. Hsc70 and Hsp90 inhibition had no effect, whereas Eeyarestatin 
(ES I), an inhibitor of both p97 and Sec61 (the translocon responsible for co-translational 
translocation), strongly reduced insertion of b5-ER, but not of the TRC40 substrate 
Synaptobrevin 2. Similarly, I found that downregulation of Sec61, while having no effect on 
Synaptobrevin, inhibited b5-ER insertion, suggesting that ES I is acting by blocking the 
translocon. Even when Sec61 and the TRC40 pathway were blocked together, however, a 
large proportion of b5-ER still reached the ER, indicating the existence of yet additional 
pathways. My results indicate that the mitochondrial outer membrane represents the 
default destination of TA proteins, and reveal the existence of multiple, redundant, but 
substrate-specific ER targeting pathways. 
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2.1   Membrane Proteins 
Membrane proteins, which comprise ∼30% of the proteome, are proteins that interact 
with, or are part of, biological membranes. Their efficient and accurate localisation is crucial 
for the structure and function of all cells, since they can be involved in signalling, intracellular 
trafficking, organelle biogenesis, and transport of a variety of molecules and ions across 
cellular membranes. Indeed, membrane proteins are targets of over 50% of all 
modern medicinal drugs (Shao and Hegde, 2011; Alberts et al., 2014). 
Many membrane proteins extend through the lipid bilayer, with part of their mass on 
either side (1,2 and 3 in Cartoon 1). These transmembrane proteins are amphipathic, i.e., 
they have both hydrophobic and hydrophilic parts. There are 
also membrane proteins completely localised in the cytosol; in this case, they can be 
associated by an amphipathic α-helix or by one or more covalently attached lipid chains 
(examples 4 and 5, respectively). The example 6 refers to membrane proteins that are 
entirely exposed outside of the cell, and that can be associated with the membrane only by 
a covalent linkage to phosphatidylinositol.  
Some membrane proteins, like the ones in examples 7 and 8, are called 
peripheral membrane proteins, since they are bound to the membrane by non-covalent 
interactions with other membrane proteins. Because of this characteristic, peripheral 
membrane proteins can be extracted from the membrane by gentle extraction procedures 
(for example solutions of very high or low ionic strength or of extreme pH). All the rest of 
membrane proteins cannot be released in these conditions, as they are tightly associated 
with the membrane, therefore being called integral membrane proteins (IMPs) (Alberts et 
al., 2014). 
Most integral proteins are embedded in membranes by hydrophobic α-helical 
sequences, of approximately 20 amino acids in length. This hydrophobic segment is called 
transmembrane domain (TMD), and it must be protected from the aqueous cytosol as soon 
as it emerges from the ribosome until it reaches the organelle, in which it will be inserted 
(Denic V., 2012). 
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Cartoon 1: Membrane proteins and association with the lipid bilayer. Most trans-
membrane proteins extend across the bilayer as (1) a single α-helix, (2) as multiple α-helices, 
or (3) as a β-barrel. Other membrane proteins are exposed at only one side of 
the membrane (4 and 5). Others are attached to the bilayer solely by a covalently attached 
lipid chain in the cytosolic monolayer (5), or via an oligosaccharide linker, 
to phosphatidylinositol in the non-cytosolic monolayer (6). Finally, many proteins are 
attached to the membrane only by non-covalent interactions with other membrane 
proteins (7,8). Reproduced from Alberts et al., 2014.  
 
 IMPs that are destined to the plasma membrane or intracellular compartments of 
the secretory and endocytic pathways are initially inserted into the endoplasmic reticulum 
(ER). Here the fate of the protein is decided: if the final topology is correctly achieved the 
protein can proceed to its final location of function; if not, quality-control pathways would 
recognise it and send the protein for degradation (Shao and Hegde, 2011). 
In order to be targeted for insertion into or translocation across membranes, proteins 
must have specific signals, which will be recognised by different machineries. Some 
examples of such signals include the secretory pathway signal sequences, mitochondrial 
targeting sequences and chloroplast leader peptides, each of which are recognised by well-
characterised, dedicated protein machinery (Alberts et al., 2014). 
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2.1.1 Insertion of membrane proteins into the ER: The Signal Recognition Particle (SRP) 
The co-translational membrane insertion mediated by the cytosolic signal recognition 
particle (SRP), the ER-localised SRP receptor (SR) and the ER-localised translocon consisting 
of the Sec61 complex, is widely accepted as the most prominent pathway for delivery of 
IMPs and soluble proteins of the secretory pathway to the ER (Elvekrog and Walter, 2015). 
This co-translational molecular machinery is conserved across all domains of life, though it 
varies in composition and function. Since the discovery of the SRP in mammals more than 
30 years ago, many groups of research have described in detail how this molecular machine 
works.  
Both SRP and SR contain GTPase domains. The GTP-dependent association of SRP into 
a tight complex with the ribosome and the nascent chain is crucial for targeting the 
ribosome–nascent chain complex (RNC) to the protein translocation apparatus at the 
membrane. In eukaryotes, SRP is composed of six proteins and one 7S RNA molecule 
(Elvekrog and Walter, 2015).  
As the protein is synthesized at the ribosome, this pathway begins when a hydrophobic 
segment of the protein, typically an N-terminal signal sequence (destined for subsequent 
removal) or a TMD close to the N-terminal, emerges from the ribosomal exit tunnel. This 
hydrophobic segment is then recognised and bound by the SRP (Mayerhofer P., 2016). The 
conserved protein of SRP, called SRP54, is responsible for signal sequence recognition and 
RNC targeting to the membrane. SRP54 contains three domains, termed the N, G and M 
domains. The C terminal, methionine-rich M domain, contains the signal-sequence-binding 
site and provides the primary contact to SRP RNA. It is connected through a flexible linker to 
the N-terminal four-helix bundle and GTPase domains (NG domain), responsible for the 
initial binding of SRP to the large subunit of the ribosome. (Elvekrog and Walter, 2015). 
This interaction occurs at the ribosomal exit tunnel and persists until the transfer to the 
receptor at the ER, which guarantees a constant shielding of the TMD during targeting. 
Furthermore, the interaction of the SRP with the TMD transiently slows translation, which 
increases the kinetic window for targeting. At the ER membrane, the SRP-RNC complex 
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interacts with the SRP receptor in its GTP-bound state. SRP and its receptor mutually 
stimulate each other's GTPase activity, with the consequent delivery of the RNC to the 
translocon (Elvekrog and Walter, 2015).  
At the ER membrane, the translocon is centrally composed of the Sec61 complex. The 
X-ray crystal structure of the archael complex revealed Sec61 is a conserved heterotrimer 
composed of α, β, and γ subunits (van der Berg et al., 2004). Sec61α is the component that 
forms the translocation channel; the channel can also open laterally towards the lipid bilayer 
providing a lateral path for TMD insertion into the membrane. The lateral opening of the 
channel was compared to the opening of a clam shell, dependent on a hinge region opposite 
to the part of the structure that opens. In the absence of a signal sequence, the lateral gate 
is closed and also the channel from cytosol to ER lumen is plugged by a short α-helix (called 
the plug). It was suggested that the bound signal sequence causes the opening of the pore 
channel by displacement of the plug. Subsequently, the work of Voorhees et al. (2014), who 
resolved the structure of mammalian Sec61 complex by cryo-EM, was important to better 
understand the mechanistic basis of translocation across the ER membrane. They provided 
a possible model for the exchange of an RNC from SRP to a translocon: a first stage of 
activation involves binding of the ribosome, which primes the Sec61 channel by opening of 
the lateral gate.  The lateral gate is an exit portal, which is opened for the entry and the 
insertion of TMDs of membrane proteins by breaking hydrophobic interactions and 
hydrogen bonds; then, in the second stage of activation, a suitable substrate can exploit the 
primed Sec61 by binding to and further opening the lateral gate. The opening of the lateral 
gate in the first step is also important for decreasing the energetic barrier necessary for 
translocation. 
Presumably, when the nascent chain is transferred from SRP to Sec61, the SRP-SR 
complex is disassembled, and the translational pause is relieved. These events are 
coordinated by the GTPase activities of SRP54, and the α and β subunits of SR (Shao and 
Hegde, 2011). The principal steps in protein targeting to the ER are summarised in Cartoon 
2. 
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Besides the Sec61 complex, several accessory factors have been proposed to assist the 
biogenesis of membrane proteins. Some of these factors are enzymes (such as signal 
peptidase complex , which removes signal peptides from nascent proteins as they are 
translocated into the ER, and oligosaccharyl-transferase complex, which transfers a 14-
sugar-oligosaccharide to nascent proteins), putative accessory factors [such as the 
translocon associated protein (TRAP) complex and translocating-chain associating 
membrane (TRAM) protein], membrane chaperones (such as Calnexin and Bip), and other 
proteins, such as ribosome-associated membrane protein 4 (RAMP4), p180, Sec62, Sec63. 
In yeast, the Sec62-Sec63 complex mediates post-translational insertion of some secretory 
proteins into the ER; the feature that determines post-translational translocation is the 
presence of a weak signal sequence, poorly recognised by SRP (Panzner et al., 1995).  Also 
in mammals the depletion of Sec62 or Sec63 leads to defects in translocation of a subset of 
secretory proteins (Lakkaraju et al., 2012; Lang et al., 2012). Sec63 appears to play a 
substrate-specific role in the initial insertion of certain precursors into the complex, i.e., it 
helps in the opening of the Sec61 complex when the signal peptides are not strong enough 
to do it. More recently, Jung et al. (2014) have shown that mutations in the N-terminal 
domain of Sec62 disrupt the interaction with Sec63 and lead to defects in translocation of 
moderately hydrophobic TMDs of single- as well as multi-spanning membrane proteins. 
The Sec62/63 complex is involved in the post-translational translocation of soluble 
precursors. The vast majority of membrane proteins, instead, is inserted by the co-
translational pathway. Nevertheless, a subpopulation of membrane proteins that inserts 
post-translationally does exist. Post-translationally inserted membrane proteins include 
those that contain TMDs that are not exposed to the cytosol long enough during translation 
for efficient recognition by ribosome-bound SRP. Translational termination of such proteins 
makes them poor SRP substrates, necessitating their recognition, targeting, and insertion by 
a purely post-translational mechanism. Examples of such proteins include extremely small 
membrane proteins of either orientation and tail anchored (TA) proteins that contain their 
only TMD within ~40 residues of the C terminus (Borgese and Fasana, 2011; Borgese N., 
2015).  
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Cartoon 2: The SRP-mediated co-translational protein targeting. A nascent polypeptide with 
a signal peptide (in orange) emerges from the ribosome (in red) and is recognised by the 
SRP. The RNC–SRP complex is then targeted to the membrane through interactions between 
the SRP and its SR.  
 
 
2.1.2 Insertion of membrane proteins into mitochondrial membranes 
 
2.1.2.1 The TOM/TIM complexes:  
The vast majority of proteins destined for the mitochondria are encoded in 
the nucleus and synthesized in the cytoplasm. So, functionality and proliferation of 
mitochondria depends on the continuous influx of proteins through the general Translocase 
of the Outer Membrane (TOM complex). The TOM works in conjunction with the translocase 
of the inner membrane (TIM) to translocate proteins into the mitochondrion (Cartoon 3). 
The central pore-forming TOM subunit is the β-barrel protein Tom40. Furthermore, the TOM 
complex comprises three receptor proteins, Tom20, Tom22, and Tom70, and three small 
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Tom proteins, Tom5, Tom6, and Tom7, which play distinct roles in the assembly and stability 
of the complex (Bohnert et al., 2015).  
Assembly of the mature multi-pore TOM complex depends on the presence of Tom22. 
This central Tom receptor spans the outer membrane with a single α-helix and exposes 
soluble domains to the cytosol and the intermembrane space that both interact with 
incoming precursor proteins. In the absence of Tom22, Tom40 and small Tom proteins are 
found in small, single-pore complexes with residual import capacity.  The peripheral Tom 
receptors Tom20 and Tom70 are composed of N-terminal α-helical transmembrane 
segments and C-terminal cytosolic domains that recognise targeting signals in the different 
classes of mitochondrial precursor proteins. Whereas Tom20 preferentially binds cleavable 
pre-sequences of inner membrane and matrix proteins, Tom70 recognises internal 
hydrophobic signals of polytopic membrane proteins (Bolender et al., 2008). 
After translocation through the TOM complex, the incoming precursors with N-terminal 
targeting sequences are handed over to the pre-sequence translocase of the inner 
membrane (TIM23). Tim50 and Tim21, two proteins in the intermembrane space, were 
found to participate in this transfer (Schulz et al., 2011). Tim50 binds to the protein emerging 
at the trans side of the TOM channel and promotes binding of the pre-sequence to the 
intermembrane space domain of Tom22 (Cartoon 3). Tim21 connects TOM and TIM 
complexes by direct but transient binding to Tom22. Importantly, the membrane potential 
(Δψ) is crucial to drive pre-protein translocation across the inner membrane: it activates the 
channel-forming protein Tim23 and exerts an electrophoretic effect on the positively 
charged pre-sequences (Bolender et al., 2008). 
Another complex of the inner membrane is the TIM22 complex, which is essential for 
the insertion of polytopic inner membrane precursor proteins. The pore-forming core 
subunit of this complex is Tim22, a hydrophobic protein which is itself a substrate of the 
carrier translocase (Rehling et al., 2003). After Tim22, other subunits of TIM complex were 
discovered: Tim9, Tim10, Tim12, Tim18 and Tim54.  As in TIM23, the import of proteins 
across or into the inner membrane via TIM22 requires Δψ, which is generated by the 
respiratory chain.  
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2.1.2.2 Insertion of MOM proteins: 
More relevant to the subject of my thesis is the mechanism of targeting/integration of 
MOM proteins. Multiple pathways have been identified, some of which involve the 
participation of the TOM complex and some of which do not. 
The MIM machinery 
The mitochondrial import (MIM) machinery plays a central role for the insertion of MOM 
proteins that are anchored by α-helical transmembrane segments. The MIM component 
Mim1 was originally identified as a protein involved in biogenesis of the TOM complex. Mim1 
forms oligomeric complexes in the outer membrane, together with Mim2 that facilitate the 
insertion of signal-anchored proteins (N-terminal transmembrane segment), like Tom20 and 
Tom70, in a process not requiring the Tom40 import channel. In addition, the MIM complex 
cooperates with the Tom70 receptor to promote the biogenesis of Ugo1, a polytopic outer 
membrane protein involved in mitochondrial fusion. Future work will be needed to elucidate 
the molecular basis of precursor interaction with the MIM complex and the mechanism of 
transmembrane segment insertion (Bohnert et al., 2015). It must be mentioned that TA 
proteins, whose TMD is close to the C-terminus, do not require the MIM complex for their 
insertion. 
 
 
 
 
2. Introduction 
 
 
 
15 
 
 
 
Cartoon 3: Outer membrane protein biogenesis. The import of MOM proteins with a single 
N-terminal α-helix (signal anchor) depends on the MIM machinery (pink). Polytopic α-helical 
proteins require MIM and Tom70, a receptor of the translocase of the outer membrane 
(TOM complex; blue). Om45, a MOM protein with a bulky intermembrane space domain, 
depends on TOM, TIM23 and MIM. Till date, a proteinaceous insertion machinery has not 
been identified for TA proteins. Reproduced from Bohnert et al., 2015. 
 
2.1.2.3 β-barrel proteins: 
In eukaryotic cells, β-barrel membrane proteins are exclusively found in the outer 
membrane of endosymbiotic organelles like mitochondria, which derived from the outer 
membrane of Gram-negative bacteria. These proteins rely on a two-step import, with the 
transfer from the TOM complex to the sorting and assembly machinery - SAM (Ulrich et al., 
2014). The small TIM proteins help in this process, by guiding the hydrophobic β-barrel 
proteins through the aqueous intermembrane space to the SAM complex in the outer 
membrane (Cartoon 4). Here, SAM complex recognises β-barrel proteins by a β-signal in the 
C-terminal β-strand. This two-step mechanism is one evidence of the endosymbiotic 
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ancestry of mitochondria, since it is comparable to the β-barrel assembly machinery in 
bacteria (BAM). Indeed, Sam50, the central essential subunit of the SAM complex is a β-
barrel protein itself and related to BamA of the BAM. TOM and SAM complexes directly 
associate to form a transient supercomplex in the outer membrane, where Tom22 plays a 
crucial role for the assembly and efficient transfer of β-barrel precursors. In the SAM 
complex Sam50 acts together with another essential subunit, Sam35, and two further 
subunits, Sam37 and Mdm10. (Ulrich et al., 2014; Höhr et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
Cartoon 4: Import of β-barrel proteins. The TOM and SAM machineries form a supercomplex 
for β-barrel protein import. Reproduced from Höhr et al., 2015. 
 
 
2.1.3  Insertion of membrane proteins into peroxisomes 
 
Peroxisome membrane proteins (PMPs) play essential roles in the biogenesis of this 
organelle and in co-ordinating peroxisomal metabolism with pathways in other subcellular 
compartments through transport of metabolites and the operation of redox shuttles 
(Theodoulu et al., 2013). Early studies indicated that PMPs are synthesised on free 
polysomes in the cytosol and subsequently inserted post-translationally into the membranes 
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of pre-existing peroxisomes. This process requires both cytosolic factors and proteinaceous 
components at the peroxisomal membrane. Three peroxins, namely PEX3, PEX16 and PEX19, 
were identified to be essential for the post-translational targeting and insertion of PMPs into 
the peroxisomal bilayer in several species (Cartoon 5) (Mayerhofer P., 2016). 
PEX19 is a predominantly cytosolic protein with a conserved C-terminal farnesylation 
site. This protein serves as a PMP chaperone, preventing aggregation and degradation of 
newly synthesized peroxisomal proteins (Theodoulou et al., 2013). PEX19 has been shown 
to bind to a broad range of PMPs at their specific peroxisome targeting signal, termed mPTS. 
PMPs may contain single or multiple mPTSs, which are composed of a cluster of positively 
charged residues (sometimes mixed with hydrophobic residues) flanked by one or two TMDs 
(Mayerhofer P., 2016).  
Algorithms have been developed for the in silico prediction of mPTSs, and based on 
mPTS content and mPTS properties, PMPs were initially classified into two groups: class 1 
PMPs (harboring a mPTS1) rely on their interaction with PEX19 to be post-translationally 
imported into peroxisomes, whereas the mPTS2 of class 2 PMPs are PEX19-independent and 
traffic to peroxisomes via the ER. Initially strictly based on whether or not a mPTS binds to 
PEX19, PMPs were later sorted by new criteria, for instance ER passage or PEX16-
dependence (Buentzel et al., 2015; Theodoulou et al., 2013).  
Except for yeast TA PMPs, so far only PEX3 and PEX22 were identified to belong to class 
2. Hence, all other known PMPs belong to class 1 and thus depend on PEX19-binding for 
their peroxisomal targeting. The way that this happens is the following: after the formation 
of PEX19·cargoPMP complexes in the cytosol, PEX19 docks on PEX3 at the peroxisomal 
membrane, thereby forming a trimeric PEX3·PEX19·cargoPMP complex. 
Besides PEX19 and PEX3, a third peroxin plays a key role in early peroxisomal membrane 
genesis in mammals: PEX16. This integral PMP was reported to act as receptor for 
PEX3·PEX19 complexes at the peroxisomal membrane. However, this role of PEX16 is not 
conserved among species, and most yeasts, including S. cerevisiae, lack a PEX16 homolog 
(Mayerhofer, P. 2016). 
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Cartoon 5: Post-translational insertion of PMPs. Pex19 binds to PMPs and transports them to 
the peroxisomal membrane, where it docks with a complex containing Pex16 and Pex3.  
 
 
2.2 Tail-anchored proteins 
 
The features and biogenetic pathways of TA proteins have been discussed in several 
reviews during the past years (Borgese et al., 2003; Borgese et al., 2007; Rabu et al., 2009; 
Borgese and Fasana, 2011; Colombo and Fasana, 2011; Hegde and Keenan, 2011; Shao and 
Hegde, 2011; Chartron et al., 2012; Denic V., 2012; Johnson et al., 2013; Borgese N., 2015). 
The defining feature of a TA protein is the presence of a single transmembrane domain 
(TMD) at the extreme C-terminus of the polypeptide. This TMD provides a targeting signal 
for the delivery of the protein to the correct subcellular compartment and also acts as an 
anchor that retains the polypeptide in the lipid bilayer once integration has taken place 
(Borgese et al., 2007).  
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TA proteins are always oriented in the membrane of the organelle with the larger N-
terminal region facing the cytosol (Cartoon 6). This part carries out the biological function of 
the polypeptide, as exemplified in the case of the SNARE proteins, in which the cytoplasmic 
domain plays a crucial role during vesicular transport. 
When the ribosomes terminate the translation of TA proteins, the C-terminal TMD, 
which encodes the targeting information, is inside the ribosome tunnel, precluding the SRP-
mediated co-translational targeting. Therefore, TA proteins take an alternative post-
translational pathway for insertion into their target membranes - ER, MOM, chloroplast, 
peroxisomal, and prokaryotic cytoplasmic membranes. This biosynthetic route is what 
distinguishes TA proteins from classical type II membrane proteins (defined as proteins 
having a single TMD with N-cytosolic, C-exoplasmic orientation), which are delivered to the 
ER by the SRP-dependent co-translational pathway (Cartoon 6). By this biosynthetic criterion 
then - and considering that the last 40 amino acids of the nascent chain are sequestered 
within the eukaryotic large ribosomal subunit - TA proteins should be considered as such if 
the membrane-interacting domain is followed by no more than 30 residues.  
Bioinformatic analyses indicate that TA proteins are well represented in all three 
domains of life (Borgese and Righi, 2010): over 50 are predicted to be expressed in yeast 
and in excess of 300 in humans. In eukaryotes, TA proteins can be found in the 
mitochondrial, peroxisomal, chloroplast outer membranes, and in intracellular 
compartments that are connected by the secretory and endocytic pathways, including the 
ER, Golgi, plasma membrane, endosomes and lysosomes. The ER acts as the entry point for 
the many different TA proteins that occupy the compartments of the secretory pathway. 
The ER is also involved in TA protein transport to peroxisomes by an indirect pathway that is 
prevalent in yeast. MOM and plastid TA proteins are instead targeted directly from the 
cytosol to their destination (Cartoon 7). 
TA proteins play essential roles in basic cellular functions including vesicle trafficking, 
protein synthesis, protein quality control, organelle biogenesis and lipid metabolism (Table 
1). Therefore, understanding the molecular mechanism of the biogenesis of TA proteins, in 
particular the post-translational membrane insertion of TA proteins, is an important issue in 
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cell biology, with implications for physiology and pharmacology as well. An example of how 
localisation and function of TA proteins could be modulated is offered by the anti-apoptotic 
protein Bcl-2. Bcl-2 is associated both with the ER and MOM, where it exerts its biological 
activity. Studies with forms of Bcl-2 engineered to localise exclusively to the ER or to the 
MOM have shown that in the two localisations it has different functions: the ER associated 
form has been implicated in the maintenance of calcium homeostasis and, although 
protective against a limited subset of apoptogenic signals, may in some cases be more 
effective than the MOM targeted protein. Thus, cell’s response to death and survival could 
be controlled by modulation of the targeting of Bcl-2 (Schinzel et al., 2004; Borgese et al., 
2003). 
 
 
Table 1: Examples of TA proteins and their functions (adapted from Borgese 
and Fasana, 2011). 
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Because of the small number of polar residues downstream to the hydrophobic domain, 
it was initially difficult to verify the exact topology of TA proteins. This problem was 
overcome by the use of TA proteins with N-glycosylation sites engineered to the extreme 
COOH-terminal polar region. Since glycosylation takes place in the ER lumen in vivo as well 
in ER-derived microsomes in vitro, when such modification occurs it means that TA proteins 
can translocate their C-terminus across the lipid bilayer; plus, when a recombinant or in vitro 
synthesised TA protein with a N-glycosylation site is used, glycosylation can demonstrate 
that the translocation occurs post-translationally. Unfortunately, this technique cannot be 
applied to the other target membranes of TA proteins (e.g. the MOM), in which the 
transmembrane topology of the C-terminal TMD has not been unequivocally demonstrated 
yet.  
 
 
 
 
 
 
 
 
Cartoon 6: Topology of TA proteins. Panel A compares the topology of TA proteins with that 
of other single-spanning and of polytopic transmembrane proteins. Panel B shows how the 
tail anchor (red) of TA proteins (right), unlike the signal anchor (red) of classical type II 
proteins (left), is unable to interact co-translationally with SRP (brown). Reproduced from 
Borgese N. (2015). 
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Cartoon 7: Biogenetic pathways of TA proteins. After release from ribosomes, a TA protein 
(red) can insert into the ER (1), the MOM (2) or the peroxisomal membrane (3) (and into the 
chloroplast outer envelope in plant cells, not depicted here). TA proteins may also reach the 
peroxisomal membrane by targeting first to specialised ER subdomains (4), followed by 
maturation of these domains into the mature organelle (foot prints). Once targeted to the 
ER, TA proteins can then be transported through the secretory pathway (paw marks). 
Reproduced from Borgese et al., 2007. 
 
 
 
 
2.2.1 Targeting of tail-anchored proteins to the ER 
 
TA proteins are prone to aggregate in the cytosol due to the hydrophobicity of their C-
terminal TMD. Therefore, while in transit to the target membrane, there needs to be a 
mechanism by which newly synthesized TA proteins are protected from aggregation. 
Although there is some data to suggest that some TA proteins with a less hydrophobic TMD, 
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such as cytochrome b5, could integrate into membranes without the assistance of 
specialised machinery (Brambillasca et al., 2005, 2006; Colombo et al., 2009), most studies 
suggest that the biogenesis of TA at the ER involves one or more cytosolic factors. To date, 
four different cytosol-dependent mechanisms have been described for secretory pathway 
TA proteins: Hsp40/Hsc70-mediated (Rabu et al., 2008), SRP-mediated (Rabu et al., 2009), 
Get3/TRC40-mediated (Stefanovic and Hegde, 2007; Schuldiner et al., 2008; Favaloro et al., 
2010) and SND-mediated (Aviram et al., 2016). Of these, the Get3/TRC40 pathway plays the 
most important role and is by far the most well-characterised.  
 
2.2.1.1 The Get3/TRC40 pathway 
 
As mentioned before, in the co-translational pathway, SRP serves both a chaperoning 
and a targeting role, ensuring complete shielding of its hydrophobic cargo during cytosolic 
transit until the translocon is reached. Similarly, the hydrophobic TMD of TA proteins must 
be shielded from aggregation in the cytosol. The search for such a shielding/targeting factor 
led to the identification of a highly conserved, cytosolic P-loop ATPase that was named 
TRC40 for TMD recognition complex subunit of 40 kDa (Stefanovic and Hegde 2007; Favaloro 
et al., 20010). TRC40 is evolutionarily related to the bacterial arsenite transport factor ArsA 
(hence its original annotation as Asna-1, for arsenical pump-driving ATPase protein) and has 
emerged as a mammalian chaperone that maintains TA proteins in soluble state and brought 
the breakthrough that led to understanding the molecular mechanism of the post-
translational membrane insertion of TA proteins. 
In parallel with these findings, a comprehensive genetic interaction study of the early 
secretory pathway in yeasts had identified a novel protein complex involved in Golgi to ER 
traffic, termed the Golgi-to-ER Traffic (GET) complex. The GET complex is composed of Get1 
and Get2, both of which are membrane proteins, and Get3, a cytosolic ATPase (Schuldiner 
et al., 2008). Importantly, Get3 is a yeast homolog of mammalian TRC40 and it was 
discovered that its role in ER/Golgi traffic was an indirect effect, due to mistargeting of 
essential SNARE proteins in its absence. Hence, the meaning of the acronym GET was 
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changed to ‘‘Guided Entry of TA Proteins’’, and the yeast GET complex provided a basic 
framework for delineating the molecular mechanism of the post-translational membrane 
insertion pathway. The mammalian TRC40 pathway is less well characterised than the yeast 
Get3 system, however, with the exception of Get2, homologues of all the S. cerevisiae 
components are expressed in higher eukaryotes and are thought to carry out similar 
functions (Denic V., 2012). Below, both systems will be described in detail: 
 
 The GET pathway in yeast: 
 
In the GET pathway, Get3 selectively chaperones the TMDs of newly synthesized TA 
proteins in the cytosol and targets them to the ER membrane, where Get1 and Get2 
constitute a receptor complex for Get3 and drive insertion of the TA proteins into the ER 
membrane (Schuldiner et al., 2008). The sum of biochemical and structural evidence has 
revealed a surprisingly elaborate pre-targeting mechanism that facilitates TMD recognition 
by Get 3.  
An in vitro reconstitution study of the GET complex demonstrated that Get1, Get2 and 
Get3 are sufficient for mediating the post-translational membrane insertion of TA proteins 
(Schuldiner et al., 2008). However, in addition to these three core components, the yeast 
GET pathway has been shown to employ three additional factors, Stg2 (small, glutamine-
rich, tetratricopeptide repeat protein 2), Get4 and Get5. Entry of newly synthesized TA 
proteins into the GET pathway begins with efficient capture by Sgt2, through binding of its 
C-terminal region to the TMDs of TA proteins soon after release from the ribosomes. This 
chaperone shields TMDs after they are released from the ribosome to prevent TA protein 
aggregation in the cytosol or mistargeting to mitochondria. Sgt2 interacts with the Get4-
Get5 complex through the ubiquitin-like domain of Get5, serving as a platform for escorting 
newly synthesized TA proteins to Get3 (Chartron et al., 2010; Denic V., 2012).  
The structural and biochemical studies of Get3 indicate that it is a homodimeric ATPase 
that switches between open and closed conformations depending on the nucleotide 
loading, the TA protein loading and the binding proteins (Mateja et al., 2009).  In the ATP-
bound state, Get3 adopts the closed conformation favourable for binding to the TMDs of TA 
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proteins. The binding of the Get4-Get5 complex to ATP-bound Get3 inhibits the ATPase 
activity of Get3, thereby priming Get3 for capturing the TA proteins (Gristick et al., 2014). 
Upon receiving the TA proteins from Sgt2, Get3 activates the ATPase activity but delays ADP 
release, leading to formation of the ADP-bound Get3-TA protein complex competent for ER 
targeting.  
The integral membrane proteins Get1 and Get2 form the ER membrane receptor 
complex required for TA-insertion by Get3. The flexible cytoplasmic domain of Get2 initially 
captures the Get3/TA-protein complex. As Get3 approaches the membrane, Get1 displaces 
Get2 and then facilitates a transition from closed to open Get3 (Mateja et al., 2009; Stefer 
et al., 2011).  Indeed, the coiled-coil region of Get1 inserts like a wedge into the TA binding 
groove of Get3, forcing it into the open conformation with the consequent release of the TA 
to the bilayer. It has also been observed that the TMDs of Get1 and Get2 interact with the 
TMD of the TA protein near the cytosolic side of the ER membrane. These transmembrane 
interactions facilitate release of the TA protein from the Get3 and mediate the subsequent 
entry of the TA protein into the ER membrane. Therefore, it has been suggested the TMDs 
of Get1 and Get2 are not simple membrane anchors for their cytoplasmic domains but 
constitute a membrane insertase for TA proteins (Wang et al., 2014). 
Importantly, whereas mutations in components of the GET system are lethal in higher 
eukaryotes, yeast cells survive in their absence. Nevertheless, deletion of the GET3 gene in 
yeast leads to several, seemingly unrelated phenotypes, including hygromycin sensitivity, 
copper and H2O2 sensitivity, heat sensitivity and the inability to grow on iron-limiting media 
(Schuldiner et al., 2008). Recently, a study by Voth et al. (2014) showed that upon exposure 
to ATP-depleting oxidative stress conditions, Get3 undergoes major conformational 
rearrangements, which appear to bury the proposed TA-binding site on Get3 and turn Get3 
into an ATP-independent chaperone. They have demonstrated that oxidized Get3 binds 
unfolded proteins and prevents their irreversible aggregation, protecting cells against 
oxidative stress, and that, upon restoration of normal cellular ATP levels, Get3 returns into 
its initial dimer structure and presumably releases its substrate for refolding or degradation. 
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 The TRC40 pathway in mammalian cells: 
 
 
Compared to the GET system, the TRC40 pathway employs another factor specific to 
mammals. Indeed, the pre-targeting complex, in addition to the mammalian homologues of 
Get4 and Get5 (TRC35 and Ubl4A, respectively), contains a third protein, called Bag6. Bag6 
interacts both with Ubl4A and TRC35, presumably acting as a bridge between them, as the 
Get4/5 homologues lack the features of the yeast proteins required for direct interaction 
(Chartron et al., 2012).  
Like in yeast, the newly synthesised TA substrate is first captured by the mammalian Sgt2 
homologue, known as SGTA, and then handed over to TRC40 via the pre-initiation complex, 
known as the Bag 6 complex. The Bag6 complex not only has the ability to load TA proteins 
onto TRC40, but also mediates protein degradation pathways for mislocalised membrane 
proteins, retro-translocated ER proteins and other defective proteins. When the TMD of a 
TA protein escapes TRC40 binding, the Bag6 complex captures the TMD to prevent 
undesired aggregation in the cytosol, leading to ubiquitination of the mislocalised 
membrane protein followed by proteasomal degradation.  
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Cartoon 8: The TRC40 pathway. The pre-targeting complex composed of Bag6, TRC35 and 
UBL4A (depicted in dark blue) captures the TMD (in yellow) of the TA protein soon after 
release from the ribosome, facilitating loading of the TA protein onto TRC40. CAML binds to 
TRC40, recruiting the TRC40-TA protein complex to the ER membrane. CAML and WRB 
constitute the ER membrane receptor complex for the TRC40-TA protein complex, driving 
post-translational insertion of TA proteins into the ER membrane. 
 
SGTA has emerged as a key regulator in macromolecular quality control, in addition to 
its established roles in the biogenesis of TA membrane proteins and proposed roles in 
hormone receptor signalling. Human SGTA is a 34 kDa protein made up of 313 amino acids 
that assembles as a homodimer, with each chain comprising three structural domains: a N-
terminal dimerization domain, a central tetratricopeptide repeat (TPR) domain, and a C-
terminal domain which includes a 39 amino acid glutamine rich region (Wunderley et al., 
2014; Roberts et al., 2015). SGTA shields TA proteins from the aqueous cytosol, by 
recognising and binding to the hydrophobic exposed regions, preventing them from 
misfolding and aggregation. Then, the subsequent fate of the proteins is determined: the 
protein can be refolded to their native conformation, targeted to the correct destination or 
processed for degradation. Since it was demonstrated that SGTA directly binds to Bag6 and 
the TMDs of TA proteins in the cytosol, most likely TA proteins could be passed from SGTA 
to the Bag6 complex. Furthermore, a recent structure-based study of the Bag6 complex 
suggests that SGTA can also directly hand off TA proteins to TRC40. Thus, the sorting step of 
TA proteins by the Bag6 complex in mammalian cells is more complex than in yeast (Roberts 
et al., 2015). 
As said before, TRC40 is a highly conserved ATPase and the mammalian homolog of 
yeast Get3. The mammalian ER receptor for TRC40 is now generally believed to be 
constituted by the WRB/CAML complex. Mammalian WRB (tryptophan-rich basic protein), 
which shows sequence similarity to yeast Get1, is predicted to have three TMDs and a 
cytosolic coiled-coil domain. WRB binds to TRC40 through the cytoplasmic coiled-coil 
domain, mediating the post-translational insertion of TA proteins into the ER membrane in 
mammalian cells (Vilardi et al., 2011). 
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Cartoon 9: Biological roles of SGTA. SGTA is involved in the quality control of hydrophobic 
substrates, a process mediated by its C-terminal domain in collaboration with the Bag6 
complex. The Bag6 complex interacts with SGTA via its ubiquitin-like domains (UBLs). 
Hydrophobic substrates bound to the Bag6 complex are ubiquitinated by the actions of the 
E3 ligase RNF126, thus targeted for proteasomal degradation. Additionally, SGTA’s role 
extends to the shielding of exposed hydrophobic regions on TA proteins facilitating their 
post-translational integration into the ER. This enables the handover of TA proteins to the 
downstream TRC40 targeting complex. Furthermore, SGTA has been implicated in hormone 
receptor signalling, and has been associated with viral lifecycles. SGTA’s interactions with 
Hsp70/Hsp90 chaperones via its TPR domain may provide substrate access to additional 
branches of the global cellular quality control network. Reproduced from Roberts et al., 
2015. 
 
 
 
 
2. Introduction 
 
 
 
29 
 
 
WRB is also known as congenital heart disease 5 (CHD5) protein, because the human 
gene encoding WRB is located in the Down syndrome critical region of chromosome 21 
(21q22.3) within the congenital heart disease region. WRB has been shown to regulate heart 
development in medaka fish. Although it has been shown to be 1.5 fold overexpressed in 
fetal fibroblasts of Down syndrome subjects (Colombo et al., 2016), the link of WRB to 
congenital heart disease frequently associated with Down syndrome, remains unclear.  
It was postulated that the TRC40 pathway will employ an ER membrane protein 
analogous to Get2. However, computer-based sequence similarity searches had failed to 
identify the mammalian gene homologous to yeast Get2. Yet, pulldown experiments with 
TRC40 as bait identified CAML (calcium modulating cyclophilin ligand) as a TRC40- and WRB-
interacting protein (Yamamoto and Sakisaka, 2015). CAML binds to TRC40 through the N-
terminal cytoplasmic domain and to WRB through the C-terminal TMDs. The CAML/WRB 
complex is sufficient to rescue TA protein insertion in ΔGet1/Get2 yeast cells (Vilardi et al., 
2011) and TA protein insertion competence is obtained by reconstituting the two proteins 
into liposomes (Colombo et al., 2016). Thus, although CAML and Get2 are not homologous, 
the WRB/CAML complex constitutes an ER membrane receptor for the TRC40-TA protein 
complex, and CAML represents the functional homologue of Get2 (Yamamoto and Sakisaka, 
2015). 
A very recent study carried out by Colombo et al. (2016) revealed unanticipated 
complexities in the function and regulation of the TRC40 receptor. They found that a 
stoichiometric excess of one subunit over the other does not affect TA protein insertion and, 
in agreement, that endogenous CAML is present in a 5-fold molar excess over endogenous 
WRB both in rat liver microsomes and in cultured cells. Notwithstanding this stoichiometric 
imbalance, the levels of each of the TRC40 receptor subunits depend critically on the 
presence of the other one, since the knockdown of each receptor subunit decreases the 
levels of the other one. Interestingly, in mammals the deletion of TRC40 is embryonic lethal, 
suggesting that, unless TRC40 has some other yet unknown function, at least one essential 
TA protein critically depends on TRC40 for its targeting/insertion (Borgese and Fasana, 
2011).  
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 The case of short secretory proteins: 
Another issue that has been discussed recently is the connection between TRC40 
pathway and ER targeting of secretory peptides. Because of their short length (<100 amino 
acids), these proteins may be released from the ribosome before SRP can capture them, but 
they still depend on Sec61 for translocation into the ER lumen. Surprisingly, TRC40 can 
recognise secretory peptides in vitro and promote their ER translocation by a WRB-
dependent mechanism. These findings raise the intriguing possibility that the GET pathway 
can feed certain substrates to the Sec61 channel. Specifically, the translocation of 
preprocecropin A (ppcecA) into ER derived microsomes is inhibited by lanthanum ions, and 
the small molecule inhibitor eeyarestatin I (ES I), both of which perturb Sec61 mediated 
translocation (Cross et al., 2009; Johnson et al., 2013).  
 
2.2.1.2 The Hsp40-Hsc70 mediated pathway 
 
The constitutively expressed and stress-inducible 70-kDa heat shock proteins Hsc70 and 
Hsp70, respectively, are ubiquitous molecular chaperones that bind and release 
polypeptides in an ATP-dependent cycle. Hsp70 function is regulated by and often 
dependent upon Hsp40 co-chaperones, which are defined by their homology to the DnaJ 
chaperone in Escherichia coli. Hsp40s stimulate the ATPase activity of Hsp70s and, thus, 
stabilise the Hsp70-peptide complex (Wright et al., 2008). Using an assay for ATP hydrolysis, 
a study by Fewell et al. (2004) identified and screened small molecules for their effects on 
endogenous and Hsp40-stimulated Hsp70 ATPase activity. The most important compound 
found was MAL3-101. A series of derivates with improved physicochemical attributes, 
including reduced molecular weight, increased solubility, and decreased lipophilicity were 
then synthesized. These included MAL2-11B, DMT002220 and DMT3024. On the other 
hand, MAL3-51 was found as a structurally related compound with little effect on chaperone 
function (Fewell et al., 2004; Wright et al., 2008).  These inhibitors have been used to show 
essential roles for Hsc/Hsp70 in maintaining breast cancer and multiple myeloma cell 
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survival but have been also shown to effectively inhibit the post-translational translocation 
of the yeast secretory protein, prepro-α-factor, across the ER membrane in vitro (Rabu et 
al., 2008).  
The effect of the MAL-based inhibitors was tested also on TA proteins insertion into ER-
derived microsomes and found to inhibit the integration of a subset of TA proteins (Rabu et 
al., 2008). This subset of proteins is characterised by TMDs of comparatively low 
hydrophobicity. It was therefore suggested that when multiple options are available, 
proteins with particularly hydrophobic TA regions such as synaptobrevin and Sec61β appear 
to favour TRC40 or other pathways, whilst those with a less hydrophobic TA region, such as 
cytochrome b5, use Hsc-70 mediated and/or unassisted pathways (Johnson et al., 2013).  
Presumably, the role of the molecular chaperones during post-translational targeting is 
mainly to prevent the aggregation of hydrophobic regions of polypeptide (such as tail-
anchor segments), thereby maintaining these substrates in a membrane-integration 
competent conformation (Rabu et al., 2009). Instead, a specific targeting function of these 
chaperones is difficult to envisage, as an ER receptor for Hsc70 has not been identified so 
far. 
 
2.2.1.3 The SND-mediated pathway 
 
Most secretory and membrane proteins are targeted to the translocon via SRP and its 
ER membrane-resident receptor, SR. However, a protein whose targeting element is a low-
hydrophobicity signal sequence (SS) or a TMD outside of the most N’ window, as it is the 
case of TA proteins, may be overlooked by the SRP, and would require dedicated SRP-
independent pathways for ER relay (Ast et al., 2013; Aviram et al., 2016). Indeed, a study 
from the group of Maya Schuldiner revealed that an unexpectedly large proportion of the 
ER-directed proteome, reaches the ER by SRP-independent pathways (Ast et al., 2013). 
Recently, one SRP-independent targeting system was discovered in yeast and termed SND 
system (Aviram et al., 2016). Through a systematic high-content screen in yeast, three 
uncharacterised proteins needed for correct targeting of SRP-independent substrates were 
discovered. These proteins were named SND (Srp-iNDependent): SND1 is predicted to be a 
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peripheral ribosome binding protein, and, in agreement, its GFP-fusion protein localises to 
the cytosol; SND2 is predicted to have four transmembrane domains and was shown to 
affect vacuolar Carboxypeptidase Y (CPY) processing. Interestingly, CPY is a known SRP-
independent substrate; the third protein, SND3, was shown to affect the biogenesis of yeast 
acid phosphatase, another SRP-independent substrate, and was shown to localise to the ER. 
So, analogous to the SRP-dependent pathway, this novel pathway involves a cytosolic 
component (SND1), which binds to ribosomes and, subsequently, to its heteromeric 
receptor in the ER membrane (comprising SND2 and SND3) to achieve co- or post-
translational delivery of precursor polypeptides to the Sec61 complex (Aviram et al., 2016). 
So far, a mammalian ortholog has been described only for SND2 (hSND2), which may or 
may not have the same function as its yeast ortholog and may be involved in TA protein 
targeting. Indeed, the SND proteins may have higher affinity for proteins with more central 
TMDs, but it seems that the three pathways, SRP, SND and GET, work in parallel to facilitate 
the ER targeting of proteins bearing TMDs in all possible relative positions. 
 
2.2.1.4 The SRP-mediated pathway 
 
Although SRP was thought to be involved exclusively in co-translational targeting, a 
possible unusual role of this ribonucleoprotein in post-translational targeting of TA proteins 
was suggested by work from the group of Stephen High. An in vitro crosslinking approach 
showed that the tail-anchor region of synaptobrevin 2 (Syb2) is transiently associated with 
the signal sequence-binding domain of SRP. Furthermore, the efficient membrane insertion 
of Syb2 requires an intact SRP receptor, which is consistent with the idea that SRP has a post-
translational role in the binding and delivery of TA proteins to the ER membrane (Abell et 
al., 2004; Rabu et al, 2009). This SRP-dependent mechanism was thought to favour a small 
subset of TA protein precursors with more hydrophobic TMDs. The role of SRP in TA protein 
targeting remains, however, controversial, because a previous study demonstrated SR-
independent insertion of Syb2 into ER-derived proteoliposomes (Kutay et al., 1995), and 
because the energy source for TA proteins insertion is provided by ATP hydrolysis, while SRP 
requires GTP. 
2. Introduction 
 
 
 
33 
 
 
2.2.2 Targeting of tail-anchored proteins to other organelles 
An important and only partially resolved problem is the mechanism whereby TA 
proteins escape from the GET/TRC pathway to be delivered to other organelles. Get3/TRC40, 
as well as Sgt2/SGTA have broad specificity, in that a hydrophobic stretch of sufficient length 
close to the C-terminus is the only requirement to qualify as substrate. Thus, TA proteins 
destined to organelles other than the ER must have features that exclude them from the 
GET/TRC pathway. In general, a combination of moderate hydrophobicity of the TMD and 
the presence of positive charges in the tail region appears to serve this function, at least in 
mammals (Borgese N., 2015). 
 
2.2.2.1 Mitochondria 
 
TA protein delivery to the mitochondrial outer membrane (MOM) appears to depend 
on physico-chemical features of the tails, as mentioned in the preceding paragraph, and not 
on defined signals: these proteins are generally characterised by TMDs of moderate 
hydrophobicity, flanked on one or both sides by positive charges. In fungi and plants, the 
presence of flanking positive charges does not distinguish MOM from ER-targeted TA 
proteins, and moderate hydrophobicity seems to be the only clear hallmark for MOM 
targeting. An additional TMD feature reported to favour mitochondrial targeting is the 
propensity for α-helix formation (reviewed in Borgese and Fasana, 2011). These features 
would determine escape from the GET pathway and delivery to mitochondria (Hwang et al., 
2004). 
It is currently unclear how the specific targeting of TA proteins to the MOM is achieved, 
since mitochondrial TA proteins do not utilise the general import machinery of the 
mitochondria. Although the TOM complex or Mim1 appear to be required for the insertion 
of certain MOM TA proteins (for example, Tom20 has been implicated in the import of Bcl-
2), in vitro studies carried out with four TA substrates (Bak, BclXL and OMP25 in mammals 
and Fis1 in yeast) have excluded the participation of the TOM complex (Kemper et al., 2008; 
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Setoguchi et al., 2006). In these works, the C-terminal TMD is sufficient for MOM targeting 
and none of the import components at the outer membrane is involved in the insertion. In 
addition, to date, no cytosolic components have been identified for the targeting of TA 
proteins to the MOM. Interestingly, the unique lipid composition of the MOM, in particular 
the low content of sterols, appears to be important for the targeting, at least in yeast 
(Kemper et al, 2008; Krumpe et al., 2012). These observations have led to the hypothesis 
that proteins carrying TMDs with the appropriate physico-chemical features can insert 
spontaneously into the MOM. The MOM would thus represent the default destination for 
TA proteins with moderately hydrophobic TMD, meaning that these substrates would insert 
into the MOM if they are not captured by targeting factors directing them elsewhere. This 
hypothesis is supported also by the observation that some MOM TA proteins (e.g., Fis1) can 
spontaneously insert into protein-free liposomes (Kemper et al., 2008). 
 
2.2.2.2 Peroxisomes 
 
It has been demonstrated that a sequence of positively charged residues in the extreme 
C-terminal region are required for targeting of TA proteins to mammalian peroxisomes. 
Direct insertion of TA substrates into the peroxisomal membrane is mediated by the 
chaperone PEX19, which in turn binds to its receptor, PEX3, on the peroxisomal surface. As 
mentioned in section 2.1.3, the PEX19/PEX3 couple is part of the general machinery for the 
post-translational insertion of peroxisomal membrane proteins and is not dedicated 
exclusively to TA protein targeting.   
Halbach et al. (2006) identified two PEX19 recognition sequences in the TMD and 
lumenal sequence of the mammalian TA protein PEX26, and demonstrated that the 
interaction between these sequences and PEX19 is required for delivery of PEX26 to 
peroxisomes. In the absence of the lumenal recognition sequence, PEX26 was 
inappropriately delivered to mitochondria. Similar Pex19 recognition sequences were 
identified also in yeast PEX15, a TA protein thought to be the functional homologue of 
mammalian PEX26. Subsequent studies demonstrated that the presence of positively 
charged aminoacids was an absolute requirement for the function of these recognition 
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sequences (Yagita et al., 2013). Another yeast peroxisomal PEX19-dependent TA protein is 
Fis1, which is involved in peroxisomal division. Interestingly, Fis1 is also targeted to 
mitochondrial membranes, where it fulfils a similar function. The recognition sequence for 
PEX9 is at the extreme C-terminus and is not required for mitochondrial targeting (Delille 
and Schrader, 2008; Mayerhofer P., 2016). 
In addition to direct insertion into peroxisomal membranes, ER-to-peroxisome 
trafficking is known to occur (Tabak et al., 2013). It was found that the correct localisation 
of overexpressed PEX15 to peroxisomes is GET-dependent. The GET system contributes to 
the biogenesis of PEX15, by guiding its insertion into the yeast ER, from where it is 
transported to peroxisomes. Interestingly, yeast cells lacking the GET-machinery still do 
contain functional peroxisomes, thereby suggesting that PEX15 can be additionally targeted 
to peroxisomes by a GET-unrelated mechanism, as described in the preceding paragraph 
(Mayerhofer P., 2016).  
In summary, mammalian and yeast TA PMPs may follow two distinct routes for post-
translational insertion into peroxisomes: In yeast, TA PMP are predominantly, however not 
exclusively, targeted through the ER to peroxisomes via the GET-machinery, whereas 
mammalian TA PMPs probably prefer the direct pathway for insertion into the peroxisomal 
membrane in a PEX19/PEX3-dependent process.  Similar to yeast, the plant TA peroxin APX 
is also targeted through the ER to peroxisomes. Besides the fact that the sorting signal for 
APX resides within its C-terminal tail, the implication of the GET pathway in APX trafficking 
has not been confirmed (Mayerhofer P., 2016). 
 
2.2.2.3 Plastids  
 
Chloroplast TA proteins do not seem to share any conserved sequence for targeting 
specificity. A noticeable feature of these proteins is that the hydrophobicity value of TMDs 
of chloroplast TA proteins appears to vary significantly compared to that of mitochondrial 
TA proteins, which contain a moderately hydrophobic TMD (see section 2.2.2.1). As in 
mitochondrial TA proteins, basic residues are present on both sides of the TMD to produce 
a positive net charge (Lee et al., 2014). 
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TA protein targeting to plastids has been studied for a Chloroplast Outer Envelope (COE) 
isoform of cyt b5 (AtCb5-6), for the GTPase import receptors Toc33 and 34 and for a COE 
protein (OEP9) of unknown function. The latter three TA proteins were shown to depend on 
a chaperone, AKRA2A, previously implicated in post-translational targeting of other types of 
outer envelope proteins (Dahnoa et al., 2010). However, the targeting signal of Toc33/Toc34 
is different from that of OEP9. In the case of OEP9, the targeting signal consists of a 32 amino 
acid-long hydrophilic chloroplast targeting sequence (CTS) and the TMD. Toc33 and Toc34 
also have single TMDs at their C-terminal ends, followed by CTS. However, their targeting to 
the COE depends on almost the entire protein sequence rather than TMD and CTS, raising 
the possibility that the targeting of TA proteins to plastids may not solely depend on AKRA2A 
(Lee et al., 2014). 
 
 
2.3 Spontaneously inserted tail-anchored proteins 
 
As described in section 2.2.2.1, studies on MOM targeting of TA proteins revealed that a 
number of MOM substrates are capable of inserting spontaneously into protein-free 
liposomes in the absence of any membrane or cytosolic protein (Kemper et al., 2008). This 
capacity is thought to be related to the moderate hydrophobicity of MOM TA proteins, a 
feature that would allow them to remain soluble in the aqueous environment without the 
help of chaperones (reviewed in Borgese et al., 2007; Borgese and Fasana, 2011). Most ER-
targeted TA proteins require instead chaperone-mediated delivery (section 2.2.1), however, 
cell-free studies have revealed that a few of them share with MOM TA proteins the capacity 
for spontaneous insertion into liposomes (Brambillasca et al., 2005; Colombo et al., 2009). 
Like MOM TA proteins, these are characterised by TMDs of moderate hydrophobicity. Two 
investigated spontaneously inserting ER TA proteins are described in the last section of this 
introduction. 
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2.3.1 Cytochrome b5 
Cytochrome b5 (b5) is a small heme-protein, composed of a cytoplasmic domain of 90 
amino acids and a C-terminal membrane anchor. Mammalian tissues express an ER-bound 
cytochrome b5 and a mitochondrial outer membrane isoform, which are the products of 2 
different genes. The 2 cyt b5 isoforms are located exclusively, or nearly exclusively, on a 
single target membrane (D’Arrigo et al., 1993; De Silvestris et al., 1995). Both b5 isoforms 
are electron carriers, which transfer electrons from a dedicated reductase (NADH-
cytochrome b5 reductase) to a number of acceptors. In the ER, b5 is mainly involved in lipid 
metabolism (Daily and Strittmatter, 1980; Fukushima et al., 1981), whereas the 
mitochondrial form is capable of regenerating reduced ascorbate from the oxidised, free 
radical form (Ito et al., 1981). 
Mammalian cytochrome b5 is the most thoroughly investigated TA protein capable of 
unassisted insertion. In studies from our laboratory, it was demonstrated that b5, translated 
in vitro in rabbit reticulocyte lysate (RRL) can translocate its C-terminus across the lipid 
bilayer in vitro in the absence of any membrane or cytosolic protein, and that these do not 
even facilitate the insertion process (Brambillasca et al., 2005 and 2006; Colombo et al., 
2009). Interestingly, however, the presence of even low concentrations of cholesterol in the 
vesicles inhibits the unassisted integration process (Brambillasca et al., 2005). 
Synaptobrevin 2 (Syb2) is a well-known TA substrate incapable of unassisted insertion. 
In the study of Brambillasca et al., 2006, the substitution of b5’s TMD with the one of Syb2 
converted b5 into an assisted substrate. Furthermore, point mutations decreasing or 
increasing TMD hydrophobicity of Syb2 and b5 respectively favoured or inhibited their 
unassisted insertion.  Thus, the feature of b5 responsible for its capacity to insert without 
assistance is the moderate hydrophobicity of the TMD. 
It was found many years ago that the tail region is responsible for discrimination 
between ER and MOM and, that the extreme C-terminal polar sequence, plays a crucial role 
in this process, with basic residues favouring targeting to the MOM (De Silvestris et al., 
1995).  Indeed, mutation of the C-terminal polar domain of the ER targeted protein (to which 
we refer as b5-ER) to contain a net positive charge results in a protein (b5-RR) that is 
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specifically targeted to mitochondria in vivo (Cartoon 10). Yet, in vitro, this mutant inserts 
into ER microsomes as efficiently as its wild-type counterpart (Borgese et al., 2001). This 
means that the unassisted insertion in vitro may mask chaperone-mediated targeting 
occurring in vivo. Additional possibilities that might be considered are pre-translational 
targeting phenomena, i.e., localization of mRNA's coding for differently localised TA proteins 
in close proximity to the target organelle, or post-insertion phenomena, i.e., initial 
indiscriminate insertion of a TA protein into all permissive membranes, followed by its rapid 
degradation in the inappropriate organelle. Indeed, a cytosolic factor (Msp1/ATAD1) was 
demonstrated to route erroneously inserted proteins from the MOM to degradation (Chen 
et al., 2014; Okreglak and Walter, 2014). At least for b5 localisation, however, we can 
exclude both mRNA localisation and protein degradation, because: first, microinjected b5 
protein is correctly targeted to the ER in cultured cells (Cartoon 11), indicating that the 
targeting information is in the protein and not in the mRNA; additionaly, since b5 localisation 
was assessed on cells fixed only after 15 minutes after microinjection, which makes unlikely 
that complete degradation of mislocalised protein would occur in this short time span. This 
conclusion is strengthened by the studies in S. cerevisiae, where b5 carrying an epitope with 
a consensus for N-glycosylation, is completely glycosylated after a pulse of only 5 min, 
indicating that it is all in the ER. It is unlikely that in this short time span, the protein could 
be inserted into other membranes and then be completely degraded (Yabal et al., 2003). 
 
 
 
 
 
 
 
 
Cartoon 10: Representation of b5-ER and b5-RR. The two proteins are identical in the catalytic 
domain (red ovals) and in the TMD (blue hatched rectangles), but differ in the short polar 
region downstream to the TMD (aminoacids indicated with one-letter code). 
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Cartoon 11: Microinjection of recombinant b5-ER and b5-RR in CV1 cells. Purified 
recombinant b5-ER (A) or b5-RR (B) were microinjected into CV1 cells. 15 minutes after the 
microinjection the cells were fixed and immunostained with anti-b5 antibodies, anti-Tom22 
mAbs (MOM marker), or anti-protein disufide isomerase (PDI – ER marker). Single confocal 
sections of the single channels and of the merged images are shown; scale bar = 5 µm 
(Patrizia Cassella, unpublished results). 
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2.3.2 PTP1B 
In a search for other spontaneously inserting TA proteins that target the ER, 
Brambillasca et al. (2006), analised the TMDs of known ER TA proteins and found that 
protein tyrosine phosphatase (PTP) 1B has a moderately hydrophobic TMD similar to b5. 
They therefore predicted that this protein might, like b5, be capable of unassisted insertion 
into liposomes and went on to confirm this expectation experimentally. 
PTP1B is an important regulator of diverse cellular signalling networks. For a long time, 
PTP1B was thought to reside exclusively at the ER; however, it has recently been detected 
as well in MOM from mammalian cell lines.  PTP1B’s insertion into the ER has been shown 
in vitro to proceed in the absence of membrane proteins and to be stimulated by 
Hsp40/Hsc70 chaperones (see section 2.2.1.2; Rabu et al., 2008). The heterologous 
expression of a fusion protein between mCherry and PTP1B's tail anchor in yeast mutants 
lacking major conserved ER insertion pathways (GET/TRC, SRP, and Sec62/Sec63 pathways) 
showed that its ER targeting was poorly affected, providing in vivo support for the hypothesis 
of spontaneous membrane insertion (Fueller et al., 2015).  
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The unique mechanisms by which tail-anchored (TA) proteins achieve their final 
subcellular localisation have, in the last years, attracted a great deal of interest, and 
constitute the subject of this thesis. Although the main pathway for targeting to the 
endoplasmic reticulum (ER) of TA proteins is represented by the TRC40/Get3 pathway, many 
TA proteins, i.e., those targeted to the mitochondrial outer membrane (MOM) and some ER 
targeted ones, can insert in vitro into pure phospholipid bilayers without assistance from 
any chaperone. Because in vivo they have a precise destination, it is clear that targeting 
factors must be involved, but these factors have not been identified to date.  
The aim of this thesis was to investigate the targeting of TA proteins that are capable of 
spontaneous insertion into lipid bilayers in cell-free systems. For this purpose, I have used 
as model cytochrome b5, of which two forms are known: the wild-type protein, directed to 
the ER (b5-ER), and the b5-RR protein, addressed to the MOM; the two proteins differ only 
in the last 7 amino acids at the C-terminus. 
The project is based on the following previous observations from the work of my 
laboratory: (i) the two proteins described above are faithfully targeted to the ER or to the 
MOM in transfected cells, but fail to be specifically targeted in cell-free systems based on 
the rabbit reticulocyte lysate (RRL); (ii) each of the two recombinant proteins is specifically 
targeted to the correct organelle when microinjected into the cytoplasm of cultured cells. 
The latter observation excludes that mRNA localisation or ribosome-associated factors 
account for the correct localisation in vivo, and suggest that cell-free systems, in which only 
one possible acceptor membrane is provided, do not reflect the complexities of in vivo 
targeting.  
Using methods of transfection, RNA silencing, microinjection and import assays with 
semi-permeabilised cells, I tried to understand the basis of the specificity of the "targeting" 
of both forms of cytochrome b5, by evaluating the involvement of different pathways and 
cytosolic chaperones. In summary, the main objective of this project is to define the 
molecular mechanisms underlying the unique biological properties of this class of proteins: 
How do TA proteins elect their target membranes? How do these proteins choose between 
the ER and the MOM?  
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Due to their essential roles in basic cellular functions and in the progression of diseases, 
understanding the biogenesis of TA proteins is important. Although my study was carried 
out on cytochrome b5 as model protein, it is relevant for other physiologically crucial TA 
proteins, such as those of the Bcl-2 family. 
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4.1 Plasmids and recombinant proteins 
4.1.1 Constructs 
The cytochrome b5 (b5) constructs used in this study were all available in the laboratory, 
and are schematized in Figure 1A. They were all derived from the plasmid pGb(5)AX, 
described in Pedrazzini et al. (2000). This plasmid contains the coding sequence of rabbit ER 
b5, subcloned in the KpnI, XbaI sites of pGEM4, and having a unique AgeI site at the border 
between the regions specifying the TMD and the C-terminal polar residues, and a HindIII site 
immediately downstream to the XbaI site. To express this cDNA in mammalian cells, the b5 
insert was placed under the cytomegalovirus (CMV) promoter by subcloning it into pCB6 
vector (construct 1). 
The plasmids pGEX2T, under the inducible promoter Tac, code for GST fusion proteins 
and so, are suitable for expression and purification of recombinant proteins from bacteria 
(constructs 2 - 4). The pGEM4 plasmids coding for b5-ER with a C-terminal opsin tag (b5-ops 
- construct 5), for b5 with the TMD of synaptobrevin 2 and a C-terminal opsin tag (syb2-ops 
- construct 7), and for PTP1B with a C-terminal opsin tag (PTP1B-ops - construct 6), under 
the SP6 promoter, were described previously (Brambillasca et al., 2006; Colombo et al., 
2009). These constructs contain at the C-terminus a tag derived from the N-terminal 
sequence of bovine opsin; this tag contains a site for N-glycosylation, which allows the 
detection of translocation of the protein into the ER lumen.  
The pQE80-MBP-WRBcc plasmid (construct 10), which codes for a fusion protein 
between maltose binding protein (MBP) and the coiled-coil cytosolic domain of WRB, was a 
kind gift from Fabio Vilardi (University of Goettingen - Favaloro et al., 2010, Vilardi et al., 
2011). The pQE80-MBP-WRBcc R77E plasmid (construct 11), a mutant version of WRBcc in 
which an arginine is substituted by a glutamate, was a kind gift from Stephen High (University 
of Manchester). Two other constructs used for transfection as ER markers were pRFP-KDEL 
(construct 8), obtained from Erik Snapp (Janelia Research Campus) and pEGFP-E-Syt1 
(extended-Synaptotagmin-1 – construct 9), obtained from Pietro de Camilli (Yale University 
School of Medicine). 
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4.1.2 Transformation of bacteria 
To prepare bacteria competent to incorporate exogenous DNA, the method developed 
by Hanahan (1983) was followed. Competent bacteria were stored frozen, and thawed and 
kept on ice for 10 minutes before use. In the meantime, 2-20 ng of plasmid DNA were diluted 
in 10 μl of water in transformation tubes. 100 μl of bacteria were added to the DNA solution, 
and the sample was left on ice for 30 minutes. Next, they were subjected to a heat shock 
step for 90 seconds at 42°C, thus allowing the DNA to enter the cells. After a quick cooling 
step on ice, 800 μl of SOC medium [SOB (2% Tryptone, 0.5% Yeast extract, 10mM NaCl, 
2.5mM KCl) supplemented with 20 mM glucose and 10 mM MgCl2] were added and the 
bacteria were incubated for 1h at 37°C with shaking to allow recovery. Finally, they were 
plated on a petri dish supplemented with the appropriate selection antibiotic and allowed 
to grow overnight at 37°C. 
 
4.1.3 DNA extraction 
Different procedures are available for isolating DNA plasmids grown from bacteria 
colonies. In this work, I carried out medium-scale isolation of plasmid DNA (MIDI 
preparations). The MIDI were performed according to QIAGEN Plasmid Midi kit: 
- 2 ml of LB (Luria Bertani medium: 10g Tryptone, 10g NaCl, 5g Yeast extract, pH 7.0), 
containing the appropriate antibiotic were inoculated with a single bacterial colony 
and incubated overnight at 37°C with vigorous shaking; 
- On the following day, 400 ml of LB medium were inoculated with 400 µl of the 
overnight culture, always in the presence of the antibiotic, and the sample was 
shaken overnight at 37°C. At this point, there were enough bacteria to allow a proper 
extraction of large amount of plasmid DNA; 
- Bacteria were centrifuged at 4°C, for 30 minutes at 4000 rpm; 
- The pelleted cells were resuspended in 4 ml of Buffer P1 (Resuspension Buffer); 
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- 4 ml of Buffer P2 (Lysis Buffer) were added and the tube was incubated at room 
temperature for 5 minutes. This step is to lyse cells and denature DNA; 
- 4 ml of Buffer P3 (Neutralization Buffer) were added and immediately the lysate was 
mixed by inverting the tube 4-6 times. This step is to neutralize the effects of the lysis 
buffer and to generate a K+-SDS precipitate. Under these conditions, the small 
plasmid DNA is renatured, while the large chromosomal DNA co-precipitates with 
the K+-SDS; 
- After 15 minute of incubation on ice, the sample was centrifuged at 12000 rpm at 
4°C for 40 minutes to eliminate genomic DNA and cell debris; 
- The supernatant was applied to the Qiagen-cartridge, which was previously 
calibrated with QBT Buffer; 
- The cartridge was washed 2 x 10 ml with Buffer QC (Wash Buffer) and the DNA was 
eluted with 5 ml of Buffer QF (Elution Buffer); 
- The DNA was precipitated by adding 3.5 ml room-temperature isopropanol to the 
eluted DNA and it was immediately centrifuged at 8000 rpm for 40 min at 4°C; 
- The DNA pellet was washed with 2 ml of room temperature (RT) 70% ethanol, and 
centrifuged another 10 minutes; 
- The pellet was air-dried, redissolved in TE buffer (10 mM Tris-Cl, pH 7.5 and 1 mM 
EDTA), analysed and stored at -20°C. 
 
The purity and concentration of the preparations was checked by UV absorption and agarose 
gel electrophoresis. 
 
4.1.4 Protein expression and purification from bacteria 
 
 Purification of b5-ER, b5-RR and b5-ops 
To express and purify b5-ER and b5-RR proteins in bacteria, the Glutathione S-
transferase (GST) Gene Fusion System was used, following the manufacturer's instructions 
(GE Healthcare). GST-tagged proteins are constructed by inserting a gene or gene fragment 
into pGEX vectors. Expression is under the control of the tac promoter, which is induced by 
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the allolactose analogue isopropyl β-D-thiogalactoside (IPTG). All pGEX vectors are also 
engineered with an internal lacIq gene. The lacIq gene product is a repressor protein that 
binds to the operator region of the tac promoter, blocking the expression of the downstream 
genes. When IPTG is added, it binds to lacIq and cancels the repression on the promoter, 
thus triggering the transcription of the downstream gene (Cartoon 12). 
  
 
 
 
 
 
Cartoon 12: Mechanism of induction by IPTG. 
 
The purification of GST-tagged proteins is based on the affinity of GST to the glutathione 
ligand coupled to a matrix, followed by proteolytic cutting with thrombin, which recognises 
a cleavage site present between the sequence of the GST and that of b5 (Cartoon 13). 
BL21 bacteria, transformed with plasmids coding for GST fusion proteins with the 
different b5 forms, and induced for 4 hours with 0.5 mM IPTG, were collected from 200 ml 
cultures and lysed with 16 ml of buffer containing 2% Triton-X100, 150 mM NaCl, 25 mM 
Tris-Cl pH 7.4, 0.2 mg/ml lysozyme, 10 mg/ml DNase, plus a protease inhibitor mixture. The 
sample was incubated at room temperature until its viscosity started to disappear; at this 
point, 10 mM EDTA was added and the incubation was continued for another hour at room 
temperature. Then, the lysate was clarified by centrifugation (10 000 × g for 40 minutes at 
4°C) and the soluble fraction was incubated for 1 hour at 4°C on a rotating wheel with GSH-
Sepharose 4B beads (GE-Healthcare). After removing unbound material, the beads were 
incubated with a solution containing 2 mM ATP, 10 mM MgSO4, 50 mM Tris-Cl pH 7.4 for 10 
minutes at 37°C, to remove associated chaperones. The beads were then washed 6 times 
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with cold PBS. The b5 constructs were then released by incubation for 2 hours at room 
temperature with 4 units (U) of thrombin (Sigma). The yield of the thrombin cleaved protein 
was evaluated by the BCA (bicinchoninic acid) assay (Euroclone) or by comparison of its 
Coomassie Brilliant Blue (CBB, Bio-Rad) staining with that of known amounts of bovine 
serum albumin (BSA, Thermo Fisher) after sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis. 
 
 
Cartoon 13: GST purification system. The GST fusion protein binds to the Glutathione-
Sepharose 4B resin (GS4B) and, after removing the unbound fraction, thrombin is used to 
cut GST from the protein. 
 
 Purification of MBP-WRBcc and MBP-WRBcc R77E 
The plasmid MBP-WRBcc was obtained from Fabio Vilardi and has been described 
previously (Favaloro et al., 2010; Vilardi et al., 2011). WRBcc (WRB coiled-coil) corresponds 
to the cytosolic domain of WRB. The plasmid MBP-WRBcc encodes WRBcc merged to MBP 
(Maltose binding protein), cloned into the vector pQE80 (Qiagen). The plasmid MBP-WRBcc 
R77E (Stephen High, University of Manchester), codes for a mutant, non-functional version 
of WRBcc in which an arginine is substituted by a glutamate. Like in the case of the pGEX 
plasmids, the MBP fusion proteins are under the control of an IPTG-inducible promoter. In 
this case, however, the affinity purification involves the binding of MBP to an amylose-
containing resin. The protein of interest can then be cleaved from MBP thanks to the 
presence of a TEV cleavage site. 
MBP-WRBcc and mutant MBP-WRBcc were purified from the soluble fraction of a 
sonicate obtained from BL21 cells induced by IPTG. The BL21 cells, obtained from 50 ml of 
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culture, were suspended in 2 ml of sonication buffer (200 mM NaCl, 20 mM Tris-Cl pH 7.5, 
1 mM EDTA, 1 mM DTT, 1 mM PMSF), and the cells were lysed by sonication. The soluble 
fraction was diluted 1:5 in the same buffer, and incubated for 2 hours at 4°C with 3 ml of 
packed Amylose resin (New England Biolabs). After this, the protein was eluted with a 10 
mM maltose solution (Sigma), and concentrated with the Amicon 3K Filter System (Merck). 
Also in this case the purification was checked by CBB staining of SDS-polyacrylamide gels, 
and quantified by the BCA assay. To cleave the WRBcc from MBP, the eluted fraction was 
incubated overnight at 4°C with GST-tagged TEV protease (Sigma), based on the 
concentration of each substrate (1 mg of TEV/100 mg of protein). The protease was then 
eliminated by incubation of the digested sample with Glutathione-Sepharose 4B. 
 
4.2 Cell culture, transfection and microinjection 
 
HeLa cells, a human epithelial cell line derived from cervical cancer, were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum 
(FBS), 1% penicillin/streptomycin antibiotic mix and 1% L-glutamine (all from Thermo Fisher) 
at 37°C and 5% CO2. 
 
4.2.1 Transient DNA transfection 
In transient transfection, the introduced nucleic acid exists in the cell only for a limited 
period of time and is not integrated into the genome. I used the jetPEI system (Polyplus 
Transfection) for transient transfection. jetPEI compacts DNA into positively charged 
particles capable of interacting with anionic proteoglycans on the cell surface. Upon binding 
to the cell membrane, the complexes are internalised via endocytosis. Once inside the 
endosomal compartment, the DNA is protected from degradation by jetPEI. This is in part 
due to the unique property of this polymer to act as a "proton sponge", which in turn buffers 
the pH within the endosome. This mechanism ultimately leads to rupture of the endosome 
and release of the DNA and the complexes into the cytoplasm, thereby allowing nuclear 
transport for subsequent transcription. 
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For transfection with jetPei, I followed the manufacturer's instructions. Briefly, cells 
were plated 24h before transfection in 6-multiwell plates to allow growth to 50% 
confluence. Prior to transfection, the medium was changed to remove cell debris. For each 
well, two solutions were prepared: the first one containing 2 μg of DNA, the second one 6 
μl of jetPEI; both were diluted to 100 μl of 150 mM NaCl. After mixing, the jetPEI solution 
was added to the one containing the DNA. This mixture was stored at room temperature for 
20 minutes and then added to cells. The cells were analysed 24 h later. 
 
4.2.2 RNA silencing 
 
RNA interference (RNAi) is an effective way to knock down gene expression to study 
protein function in a wide range of cell types. For my experiments, I used short double 
stranded RNA oligonucleotides, 21 nucleotides in length; this length corresponds to the size 
of endogenous interfering RNAs generated from pre-microRNA transcripts by an enzyme 
called Dicer. The RNA duplex is designed to target the chosen mRNA. The antisense strand 
of the siRNA duplex becomes part of a multi-protein complex, or RNA-induced silencing 
complex (RISC), which then identifies the corresponding mRNA and cleaves it at a specific 
site, by endonucleases called argonaute proteins.  Next, this cleaved message is targeted for 
degradation, which ultimately results in the loss of protein expression. 
For silencing procedures, cells plated in DMEM without antibiotics at approximately 20% 
confluence were transfected with RNAi duplexes with the use of RNAiMAX Lipofectamine 
reagent (Thermo Fisher). For transfection, two solutions were prepared: one containing the 
appropriate volume of siRNA (starting from stock solutions of 10 µM), and the other one 
containing Lipofectamine in a ratio 1:1 (1 µl of lipofectamine per 1 µl of siRNA); both diluted 
in Optimem (Thermo Fisher). After mixing, the siRNA solution was added to the one 
containing the Lipofectamine. This mixture was stored at RT for 20 minutes and finally added 
to cells. Parallel cultures were transfected with equal concentrations of Silencer Select 
negative control RNA (Thermo Fisher). Six hours after transfection, the medium was 
replaced with complete growth medium; cells were collected and analysed after 48h (for 
WRB and SGTA silencing) or 72h (SND2 silencing) after transfection. Specifically for Sec61, a 
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second transfection was done 24 h after the first one and the cells were collected 48 h after 
the second transfection. 
- WRB was silenced with two different siRNAs (Ambion Silencer Select siRNAs), each at a 
concentration of 5nM. The sequence of the sense strand is given: s14905 (WRB 
siRNA#1: 5’ CAGUCAACAUGAUGGACGAtt 3’); s14906 (WRB siRNA#2: 5’ 
GGGUGAUAAGUGUCGCUUUtt 3’);  
- SGTA was silenced with two different siRNAs (Ambion Silencer Select siRNAs), each at a 
concentration of 10 nM. The sequence of the sense strand is given: s12783 (SGTA 
siRNA#1: 5’ GCUUCGAACCUAAUGAACAtt 3’); s12782 (SGTA siRNA#2: 5’ 
GCCGUGCAUUUCUACGGAAtt 3’);  
- Sec61 alpha subunit was silenced with two different siRNAs (Ambion Silencer Select 
siRNAs) each at a concentration of 10 nM. The sequence of the sense strand is given: 
s30355 (Sec61 siRNA#1: 5’ CGCACGUUCUUACCCAGUUtt 3’); s26722 (Sec61 siRNA#2: 5’ 
GAGUGAUUCUAGCCUCUAAtt 3’);  
- SND2 protein was silenced with four different siRNAs (Qiagen), each at a concentration 
of 20 nM. The sequence of the sense strand is given: SND2 siRNA#1, 
5’CCUUAAGGAUGUGAUCCUAtt3’; SND2 siRNA#2, 5’ CUAUAGGGUCGUU-GAAUAAtt3’; 
SND2 siRNA#3 5’ GGGCAAAGUGGGCACGAGAtt3’; SND2 siRNA#4 
5’GGGUAUACUUAUACUCUAUtt 3’. 
 
 
 
 
 
 
 
4.2.3 Microinjection 
 
Microinjection was performed with an Eppendorf 5200 microinjector by applying a 
pressure of 80-90 hPa, which injected plasmids (in water solution at a concentration of 100-
200 ng/μl) into the nucleus of HeLa cells cultured at 80% of confluence. The microinjected 
cells were incubated 15 minutes at 37°C and then fixed with 4% paraformaldehyde for 20 
minutes. 
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4.3 Antibodies 
In this work, antibodies were used in both biochemical and immunofluorescence assays. 
The protocols used require an incubation with a primary antibody followed by an incubation 
with a secondary antibody. For immunofluorescence (IF) experiments, the secondary 
antibodies are conjugated with a fluorophore, while for Western blot (WB) experiments, the 
secondary antibodies are conjugated with peroxidase or with infrared fluorophores. 
 
 
 
 
 
4.3.1 Primary antibodies 
Primary antibodies are immunoglobulins raised against an antigenic target of interest (a 
protein, peptide, carbohydrate, or other molecule) and are typically unconjugated 
(unlabelled). Primary antibodies that recognise and bind with high affinity and specificity to 
unique epitopes across a broad spectrum of molecules are available as high specificity 
monoclonal antibodies and/or polyclonal antibodies. These antibodies are useful also to 
detect modifications mediated by processes such as phosphorylation, methylation or 
glycosylation. The primary antibodies used in this study are summarised below: 
 
Antigen Type of antibody Origin Application 
Opsin R2-15 Mouse mAb Paul Hargrave WB/IF 
Cytochrome b5 Rabbit polyclonal Produced in the lab WB/IF 
WRBcc Rabbit polyclonal Synaptic Systems WB 
TRC40 Rabbit polyclonal Produced in the lab WB 
PDI Mouse mAb Enzo Life Sciences WB 
MFF Mouse mAb Proteintech IF 
Calnexin Rabbit polyclonal Ari Helenius WB 
Tom-20 Mouse mAb Abnova IF 
Sec61α Rabbit polyclonal Richard Zimmermann WB 
SND2 Rabbit polyclonal Richard Zimmermann WB 
SGTA Chicken polyclonal Stephen High WB/IF 
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4.3.2 Secondary antibodies 
A secondary antibody binds to primary antibodies or antibody fragments. They are 
typically labelled with probes that make them useful for detection, such as peroxidase or 
fluorophore. The secondary antibodies used in this study are summarised below: 
 
Species reactivity Conjugation Origin Application 
Rabbit Peroxidase Sigma WB 
Rabbit IRDye 800CW LI-COR WB 
Rabbit Alexa Fluor 488 Life Technologies IF 
Rabbit DyLight 549 Jackson IF 
Chicken IRDye 800CW LI-COR WB 
Mouse Peroxidase Sigma WB 
Mouse IRDye 680RD LI-COR WB 
Mouse Alexa Fluor 647 Life Technologies IF 
Mouse Alexa Fluor 633 Life Technologies IF 
Mouse DyLight 549 Jackson IF 
 
 
4.4 Import assays of tail-anchored proteins 
To investigate TA protein targeting, I used a system based on semi-intact (also called 
semi-permeabilised) cultured cells (Setoguchi et al., 2006). In this system (Figure 1B), 
adherent cells are permeabilised by low concentrations of digitonin, which, because of its 
affinity for cholesterol, disrupts the permeability barrier of the plasma membrane, while 
leaving intracellular membranes intact. In this way, the interior of cells has access to added 
macromolecules. The semi-intact cells are washed, to remove the cytosol, which can then 
be replaced by an exogenous source of cytosol, manipulated as desired. In my experiments, 
I used the rabbit reticulocyte lysate (RRL) as source of cytosol. TA protein substrates were 
introduced into the system either as recombinant proteins or as the products of in vitro 
translation. 
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4.4.1 Preparation of RRL 
RRL, purchased from Green Hectares, was treated with Hemin solution (to have a 
solution of 0.65 mg/ml, I first dissolved 6.5 mg of hemin in 250 µl 1N KOH; the volume was 
then brought to 10 ml to obtain a solution containing 10 mM Tris pH 8.0, 89 % (v/v) ethylene 
glycol, and 25 mM HCl; the solution was frozen in liquid nitrogen and stored at -80 °C). Hemin 
is added because it suppresses hemin-regulated inhibitor kinase, which, by phosphorylating 
initiation factor elF2α, inhibits the initiation of translation; in the absence of hemin, protein 
synthesis in the RRL will cease after a short period of incubation. It should be noted that the 
RRL was not treated with nuclease to remove endogenous mRNA. In this way, the presence 
of EGTA to inactivate the nuclease is avoided, and thus the endogenous levels of Ca2+ are 
kept. When thawed, the following components were added (final concentrations specified): 
0.07 mM of each amino acid, 22.75 mM Hepes, 18.63 mM KOH, 17.5 mM ATP, 1.75 mM 
GTP, 17,5 mM creatine phosphate, 87.6mM KOAc, 2.2 mM MgCl2, 70 ng/μl creatine kinase, 
2 mM glutathione and 1 μM taxol.  
 
4.4.2 In vitro transcription and translation 
b5-ops, syb2-ops and PTP1B-ops in pGEM4 were transcribed by SP6 polymerase 
(Promega) for 1 hour at 37°C (5 µg of DNA per 20 µl of transcription), and the resulting 
synthetic RNA was translated for 1 hour at 32°C in RRL (20 μl of the transcription reaction 
plus 100 μl of RRL mixture), treated as described in the preceding section. In both processes, 
RNasin (Promega) was added to avoid RNA degradation. In some experiments (the ones with 
the PTP1B protein), the translation was done in the presence of 1 mCi/ml 35S-methionine 
(Perkin Elmer) omitting the addition of non-radioactive methionine to the mixture. For all 
the others, the translation was carried out with unlabelled methionine, and the translation 
products were revealed by western blotting with anti-opsin antibodies. In all cases, 
translation was blocked by addition of 300 μg/ml cycloheximide (Sigma), and ribosomes 
were removed (55000 rpm for 1 hour at 4°C) before carrying out post-translational insertion 
assays. 
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4.4.3 Permeabilisation of HeLa cells and incubation with TA substrates 
 
The protocol was adapted from Setoguchi et al. (2006). This procedure allows the 
evaluation of the localisation of proteins in a system intermediate between in vivo cultured 
cells and a cell-free system.  
HeLa cells were seeded onto 22x22 mm or Ø 15 mm coverslips in 6 or 12-multiwell 
plates and grown to ≥80% confluence. Cells were washed twice with import buffer (0.25 M 
sucrose, 2.5 mM Mg2+(OAc)2, 25 mM KCl, 1 μM taxol, 20 mM Hepes-K+ pH 7.4), incubated at 
26°C for five minutes in 800 µl the same buffer containing of 25 μM digitonin (Calbiochem), 
washed two times with import buffer and then exposed to 300 μl (or 120 μl for Ø 15 mm 
coverslips ) of KHM buffer (110 mM K+OAc, 20 mM Hepes-K+ pH 7.4, 2 mM Mg2+(OAc)2, 1 
μM taxol) or RRL containing either the in vitro translated (b5-ops, syb2-ops, PTP1B-ops) or 
the recombinant protein (0.5 µg of b5-ER, b5-RR or b5-ops). After incubation at 26°C for 1 
hour, the cells were washed 3 times with KHM buffer. Targeting of TA proteins to the ER or 
mitochondria was assessed by IF analysis of the cells fixed with 4% paraformaldehyde 
(section 3.6). Alternatively, integration of TA proteins into the ER of semi-intact cells was 
monitored by evaluating the percentage of glycosylation of the C-terminal opsin epitope. To 
this end, cells were lysed with 100 μl of lysis buffer (1% sodium dodecyl sulfate (SDS), 0.1 M 
Tris-Cl pH 8.9 supplemented with protease inhibitors) and heated for 2 min at 90°C.  
 
 
4.4.4 Pharmacological treatment of the RRL 
 
After translation of the investigated TA substrate, the RRL was treated with one of the 
inhibitors listed in the table below. The Hsp70 inhibitors, obtained from Jeffrey Brodsky 
(University of Pittsburgh), are described in Fewell et al. (2004) and Wright et al. (2008). 
WRBcc corresponds to the coiled-coil domain of WRB and acts as decoy receptor for TRC40 
(Vilardi et al., 2011, see section 3.1.4). The table also lists the conditions of the treatment 
and the solvent in which each substance was dissolved. Controls were always carried out 
with equal volumes of the vector.  
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At the end of the treatment, the RRL containing the in vitro translated TA protein was 
added to adherent semi-intact cells. When the recombinant protein was used, it was added 
at the end of the treatment and before incubation with cells.  
 
Compound Source 
Concentration 
and solvent 
Time of 
treatment 
Action 
MAL2-11B Jeffrey Brodsky 100 µM in DMSO 15 min RT Hsp70 inhibitor 
MAL3-51 Jeffrey Brodsky 100 µM in DMSO 15 min RT 
Hsp70 false 
inhibitor 
DMT 002220 Jeffrey Brodsky 100 µM in DMSO 15 min RT Hsp70 inhibitor 
DMT 003024 Jeffrey Brodsky 100 µM in DMSO 15 min RT Hsp70 inhibitor 
Geldanamycin Calbiochem 10 μM in DMSO 15 min RT Hsp90 inhibitor 
WRBcc Fabio Vilardi 5 μM in KHM 15 min RT 
Inhibitor of 
TRC40 pathway 
WRBcc R77E Stephen High 5 μM in KHM 15 min RT 
TRC40 false 
inhibitor 
Eeyarestatin I (ES 
I) 
Sigma 
10, 20 and 
100μM in DMSO 
1h on ice 
Inhibitor of 
ERAD 
Eeyarestatin 35 Stephen High 
10, 20 and 100 
μM in DMSO 
1h on ice 
Inactive 
analogue of ES I 
DBeQ Sigma 20 μM in DMSO 1h on ice p97 inhibitor 
 
 
 
4.4.5 TRC40 depletion 
 
Protein-G-Sepharose (150 µl) was incubated with 150 µl anti-TRC40 antibody (20 mg/ml 
total Immunoglobulin fraction generated by NH4sulfate precipitation,) for 1 hour at 4°C. 
After removing the supernatant, the resin was incubated with 350 µl of RRL for 1 hour at 
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4°C, and the depleted lysate was recovered after removal of the beads by centrifugation. As 
control, a solution of unrelated IgG was used instead of the antibody (mock depletion). 
Depletion of TRC40 was checked by western blotting. 
 
4.4.6 ATP depletion 
 
ATP was depleted from RRL with a hexokinase/glucose trap (adapted from Yabal et al., 
2003). The ATP-dependent phosphorylation of glucose to form glucose 6-phosphate is the 
first reaction of glycolysis, and is catalysed by the enzyme hexokinase, resulting in the 
depletion of all available ATP. The RRL was first prepared with all components except 
creatine phosphate, ATP, GTP and creatine kinase. Then, a solution containing 30 mM 
glucose and 2.5 μg/ml hexokinase (both from Sigma) was added.  
 
4.5 Biochemical analyses 
 
 
4.5.1 Carbonate extraction 
 
A simple method for determining if an integral membrane protein has achieved stable 
insertion into the bilayer is alkaline extraction. Commonly, preparations are subjected to a 
sodium carbonate solution (pH 11-12). Upon treatment with sodium carbonate, protein-
protein interactions are disrupted, concomitantly stripping attached peripheral proteins, 
while protein-lipid interactions remain and the bilayer is otherwise intact (Fujiki et al., 1982). 
For carbonate extraction analysis, cells were collected with cold PBS, and homogenised by 
repeatedly passing the cell suspension through a 26G × ½’’ needle; the total homogenate 
was then incubated with and equal volume of 0.2 M Na2CO3 for 30 minutes on ice. An aliquot 
was set aside as input, and the rest of the sample was ultracentrifuged at 60.000 rpm (rotor 
TLA 100.3, Beckman) for 1 hour at 4°C, in order to separate carbonate-soluble and insoluble 
proteins. The pellets were resuspended in the original volume of 0.1 M Na2CO3, and equal 
aliquots of pellet and supernatant were analysed by SDS-PAGE/WB. 
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4.5.2 Treatment with glycanase 
 
The enzyme N-glycanase F (PNGase F, New England Biolabs) was used to remove N-
linked glycans from our constructs, according to the instructions of the manufacturer. In 
vitro synthesized or recombinant proteins were first immunoprecipitated. To this end, 60 µl 
of sample were diluted with eleven volumes of IP buffer (100 mM NaCl, 50 mM Hepes-K pH 
7.4 and 1% Triton X-100); the sample was then supplemented with 40 µl Protein-G-
Sepharose (50 % slurry) and 8 µg IgG/ml of anti-opsin mAb. After incubation overnight at 
4°C in a rotating wheel, the beads were collected by centrifugation and washed once with 
IP buffer and once with H2O. 20 µl of 1× Denaturing Buffer (0.5% SDS, 40 mM DTT) was 
added and the glycoprotein was denatured by heating the sample at 95°C for 5 minutes. 
After centrifugation, the eluate was divided in 2 aliquots, one for digestion and one for 
control. To 10 µl of eluate, 2 µl 10× G7 Reaction Buffer (500 mM sodium phosphate pH 7.5), 
2 µl 10% NP40 and 6 µl H2O were added. PNGase F (1 µl) was added only to the digestion 
aliquot and both samples were incubated at 37°C for 1 hour.  The reduction in molecular 
weight caused by deglycosylation was analysed by SDS-PAGE/WB (section 3.5.5). 
 
4.5.3 Determination of glycosylation with Concanavalin beads 
 
This technique was used to analyse the glycosylation of PTP1B, since the glycosylated 
protein migrates very close to the non-glycosylated one. Concanavalin A (Con A) is a 
tetrameric metalloprotein isolated from Canavalia ensiformis (jack bean). Con A binds 
molecules containing α-D-mannopyranosyl, α-D-glucopyranosyl and sterically related 
residues. Concanavalin A coupled to Sepharose is routinely used for separation and 
purification of glycoproteins, polysaccharides and glycolipids. 
To perform this protocol, cells were recovered with Binding Buffer (20 mM Tris-HCl pH 
7.4, 0.5 M NaCl, 1% Triton and protease inhibitors) and, after elimination of nuclei, the 
supernatant was incubated with ConA Sepharose resin (GE-Healthcare) overnight in a 
rotating wheel at 4°C, in a ratio of 15 µl packed ConA beads per 150 µg of protein. The 
mixture was then centrifuged; the resulting supernatant, corresponding to the 
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unglycosylated fraction, and the beads, containing the glycosylated proteins, were analysed 
by SDS-PAGE. 
 
4.5.4 SDS-PAGE and Western Blot 
 
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis, is a technique 
widely used in biochemistry to separate proteins according to their molecular mass. This is 
because the ionic detergent SDS denatures and binds to proteins to make them evenly 
negatively charged. Thus, when a current is applied, all SDS-bound proteins in a sample will 
migrate through the gel from the negatively charged electrode (cathode) towards the 
positively charged one (anode). Besides the addition of SDS, proteins may optionally be 
briefly heated to near boiling in the presence of a reducing agent, such as mercaptoethanol, 
which further denaturates the proteins by reducing disulfide linkages, thus overcoming 
some forms of tertiary protein folding, and breaking up quaternary protein structure.  
In this study, before loading, samples were boiled for 2 minutes after adding 1/2 of 
volume of Denaturation Buffer (DB) 3X (3% β mercaptoethanol, 25.5% glycerol, 6% SDS, 60 
mM Tris-HCl pH 6.8, 0.03% bromophenol blue). Polypeptides were then separated on 
polyacrylamide gels of appropriate concentration, depending on the analysed protein. 
Separated polypeptides were visualised by CBB staining. When the in vitro translation with 
35S-methionine was analysed, the resulting radioactive gels were stained with CBB, dried and 
imaged with the Storm phosphoimager (GE-Healthcare). Band intensities were quantified 
with Image Quant TL 7.0 software. 
More commonly, recombinant or in vitro synthesized polypeptides were visualised by 
Western Blotting (WB). This technique uses specific antibodies to identify proteins that have 
been separated by gel electrophoresis. With the application of an electrical current, the 
proteins are transferred from the gel to an adsorbent membrane where they become 
immobilised as a replica of the gel’s band pattern. The membrane can then be further 
processed with antibodies specific for the target of interest, and visualised using secondary 
antibodies and detection reagents. In this work, proteins were transferred onto 0.2 μm 
nitrocellulose membrane (Perkin Elmer). The blots were probed with the indicated primary 
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antibodies, followed by peroxidase- or infrared- conjugated secondary antibodies (see 
sections 3.3.1 and 3.3.2). In the first case, bands were visualised with ECL Western blotting 
detection system (Perkin-Elmer). In the second case, blots were scanned with the Odyssey 
CLx Infrared Imaging System (LI-COR, Bioscience) and the bands were quantified with Image 
Studio software (LI-COR, Bioscience). 
 
 
4.6 Immunofluorescence 
The cells grown on glass coverslips were fixed for 20 minutes at RT with 4% 
paraformaldehyde in 120 mM phosphate buffer pH 7.6. Fixed cells were generally stained 
with antibodies under high salt conditions (procedures 1 and 2, below). Incubations with 
antibodies was done by placing the coverslips on top of a small drop of solution, deposited 
on a layer of parafilm in a humid chamber. 
Procedure 1: This was used for the detection of cytosolically exposed epitopes in cells 
previously permeabilised with digitonin (section 3.4.3). In this case, additional 
permeabilisation was not required. Formaldehyde was quenched and nonspecific binding 
sites saturated by incubating the coverslips over a drop of GDB (gelatin dilution buffer: 0.1% 
gelatin, 40 mM phosphate buffer pH 7.6, 0.45 M NaCl) for 1 hour. The cells were then 
incubated for 2 hours with primary antibody diluted in GDB, followed by 3 washes in High 
Salt buffer (HS = 20 mM Tris-HCl pH 7.4, 500 mM NaCl), and incubation with the secondary 
antibody diluted in GDB for 1 hour. At the end the coverslips are washed 3 times in HS, once 
with PBS, once with H2O, mounted with Mowiol (Sigma), and sealed with nail polish.  
Procedure 2: This was used for cells not previously permeabilised or to detect epitopes 
in the lumen of organelles, whose delimiting membrane would not be permeabilised by the 
previous digitonin treatment. The procedure is identical to procedure 1, except that the GDB 
is supplemented with 0.3% Triton X100.  
Confocal images were acquired using a LSM 510 META (Carl Zeiss) connected to an 
Axiovert 200M microscope (Carl Zeiss), or with the Confocal Spinning Disk LCI Ultraview 
(Perkin Elmer) system connected to an Axiovert 200M microscope (Carl Zeiss). In all cases, 
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the images were acquired using a 63X magnification Plan-Apochromat lens. Single confocal 
sections are shown in the illustrations, which were prepared with Photoshop software. 
 
4.6.1 Image analysis 
Colocalisation of cytochrome b5 with mitochondria or endoplasmic reticulum markers 
were quantified by Mander’s colocalisation coefficient (ImageJ “JACoP” plug-in analysis) 
(Manders et al., 1992; Bolte and Cordelieres, 2006), which corresponds to the fraction of 
overlapping pixels between two channels. This coefficient will vary from 0 to 1, the former 
corresponding to non-overlapping images and the latter reflecting 100% co-localisation 
between both images.  
Before running the JACoP plug-in, the background of each image was subtracted and a 
region of interest (ROI) for each cell to be analysed was manually drawn. 
 
 
4.7 Statistical analysis 
All quantitative data are presented as mean ± SEM. The number of experiments is indicated 
in the legend of each figure. When the errors bars are not indicated, it is because the graph 
represents a single experiment. In the case of image analysis, images were pooled from at 
least 3 independent experiments. Comparisons between two groups were carried out by 
paired or unpaired Student’s t-test (Excel), as indicated in the figure legends. Multiple 
comparisons among groups were carried out by One-Way ANOVA (Prism) and Bonferroni's 
post-test.  In the figures, the following symbols are used:  ns (not significant), p > 0.05; *, p 
≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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1. Cytosolic factors are required for faithful targeting of b5-ER but not of b5-RR  
in semi-intact cells. 
 
As described previously in the introduction, each of the two recombinant cytochrome 
b5 forms, b5-RR and b5-ER, is specifically targeted to the correct organelle when 
microinjected into the cytoplasm of cells. In addition, the two proteins are faithfully targeted 
to the ER or to the MOM in transfected cells, but fail to be specifically targeted in cell-free 
systems based on the rabbit reticulocyte lysate (RRL) (Borgese et al., 2001).  
Based on this, we wanted to establish conditions in semi-intact cells to reproduce the 
in vivo targeting. The semi-intact procedure consists in treatment of cultured cells with low 
concentrations of digitonin, which permeabilises the plasma membrane, while leaving 
intracellular membranes intact. For my experiments I used the constructs 2 and 3 described 
in Figure 1. b5-RR is identical to b5-ER except for the last residues at the C-terminal, which 
are replaced with two arginines; this protein localises in vivo to the MOM and, as b5-ER, is 
able to be inserted into liposomes without assistance.  For these experiments, b5-RR and 
b5-ER were purified as recombinant fusion proteins, isolated from bacteria transformed 
with the corresponding plasmids (Figure 2, A and B). HeLa cells were transfected for 24 hours 
with RFP-KDEL, which serves as ER marker. The day after the transfection, each recombinant 
protein, in the presence of buffer (KHM) alone or of cytosol (RRL) was incubated with semi-
intact cells for 1 hour at 26°C (see Methods). The cells were then washed, fixed and analysed 
by immunofluorescence.  The antibodies used were the anti-b5 (in green) and anti-Tom20 
as MOM marker (in blue).  
We found that b5-RR localised to the MOM both in KHM and RRL, as can be seen by the 
co-localisation of b5 with Tom20 (Figure 3A). This means that this protein does not need 
cytosolic factors to reach its final destination, since in buffer there was already 75% of 
colocalisation to the MOM; however, in RRL this percentage increased to almost 90% (Figure 
3A), suggesting that factors in the RRL could facilitate targeting to the MOM.  We often 
observed swollen mitochondria, with fragmentation of the mitochondrial network. This can 
be explained by the procedure of cell permeabilisation and maybe by the overloading of 
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protein to this organelle. Despite this altered morphology of mitochondria, what is 
important to mention is that this structure is easily distinguisable from the structure of the 
ER, given by RFP-KDEL marker. 
When we looked at b5-ER’s localisation, very surprisingly we found that in buffer it also 
localised to the MOM, in the same way as b5-RR. After quantification, we concluded that 
the target of b5-ER to MOM is as efficient as b5-RR, with a percentage of co-localisation of 
almost 80% (Fig. 4A). On the contrary, when b5-ER was incubated with RRL, the majority was 
localised to the ER, as quantified by the co-localisation with the marker RFP-KDEL (∼65%, 
Figure 3B and 4B). This is particularly well observed in the inset of Figure 3B, where the 
nuclear envelope indicated by the arrow is a clear evidence of ER localisation. Despite the 
fact that there was still some b5-ER mislocalised to the MOM, this is significantly different 
from the b5-RR colocalisation to the MOM (Figure 3A and 4A).  The same thing is true for 
the opposite situation: despite there was some b5-RR localised to the ER in RRL, the 
colocalisation of b5-ER to with the ER marker in RRL was significantly higher.  
The presence of some b5-ER on the MOM is in agreement with studies on the location 
of the two endogenous isoforms: while the mitochondrial isoform is exclusively present at 
the MOM, a small proportion (about 5%) of the ER form is also at the MOM (D'Arrigo et al., 
1993). In addition, the localisation of b5-ER to the MOM assessed by Mander's coefficient 
may be an overestimate, due to incomplete resolution between the ER and the MOM. 
Indeed, the ER marker, RFP-KDEL, was also found to partially co-localise with TOM20 
(approximately 30%, data not shown), although it is most likely that there is no 
mitochondrial localisation of this marker. The same reasoning probably explains the 
percentage of b5-RR estimated to be present on the ER by Mander's coefficient. 
The results presented in Figs. 3 and 4 led to the conclusion that b5-ER needs cytosolic 
factors to reach its organelle and to avoid mislocalisation to the MOM; on the other hand, 
b5-RR reaches its specific organelle in both conditions, suggesting that the mitochondria is 
somehow the default destination of TA proteins. 
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2. The targeting of b5-ER to the ER is energy dependent. 
 
Once we have established that, in semi-intact cells, b5-ER is faithfully targeted in 
presence of RRL, we then asked if this targeting was energy dependent. To address that, we 
prepared a RRL depleted of ATP via a hexokinase/glucose trap (see Methods). 
As expected, for b5-RR we saw no difference in its localisation to the MOM with or 
without energy. As accessed by the Mander’s coefficient quantification, the difference in 
localisation to the MOM between normal RRL and energy depleted RRL was not significant. 
Nevertheless, the MOM targeting was higher in both these two conditions when compared  
to buffer, suggesting that RRL could have a minor role in the targeting process.  
Differently, b5-ER’s localisation to ER was significantly decreased in the energy 
depletion condition. Indeed, whereas in RRL there was approximately 65% of b5-ER co-
localising with RFP-KDEL, in energy depleted RRL this value is less than 40% (Figure 4B). 
Conversely, co-localisation of b5-ER with the MOM in this condition was significantly higher 
than in normal RRL, which means that at least some part of the protein is relocated to the 
MOM when the targeting to the ER is not possible. 
Regarding b5-RR’s localisation to the ER, we observed that the small population that was 
colocalising to the ER decreases when it was incubated with RRL depleted of energy, once 
again supporting the idea that energy-dependent chaperones are required to reach this 
organelle. 
 
3. With energy depletion there is less insertion into membranes. 
 
 
 
 
Parallel with the finding that the targeting of b5-ER to the ER is energy-dependent, we 
also observed that the intensity of b5-ER’s cell-associated fluorescence was much lower in 
the condition of energy depletion compared to the condition with complete RRL (Figure 4C). 
This might have happened due to the fact that the protein, in the absence of cytosolic 
chaperones, remains aggregated, i.e., non-functional, in the cytosol. Despite the fact that a 
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part can be relocated to the mitochondria, as said before (Figure 4A), the rest that is not 
able to reach the ER is probably washed away at the end of the incubation period. 
As shown in Fig. 4C, the cell-associated intensity of fluorescence of b5-RR was also 
decreased after incubation with energy-depleted RRL. In this case, the explanation is not so 
obvious since as we have observed previously, b5-RR does not require RRL to be targeted to 
the MOM. In the energy depletion condition, it is likely that some b5-RR is trapped with ATP-
dependent chaperones and is thus unable to reach its target membrane. 
 
 
4.  b5-RR and b5-ER are correctly integrated into the lipid bilayer. 
 
Once we assessed by immunofluorescence the localisation of b5 forms to the ER and/or 
to the MOM, we then wanted to prove that they were inserted and not simply associated 
with membranes. To distinguish between these two situations, we performed a carbonate 
extraction experiment. Upon incubation of b5-ER and b5-RR with semi-intact cells, the 
homogenates of cells were treated with sodium carbonate, which maintains protein-lipid 
interactions while disrupting protein-protein interactions (see Methods). After separation of 
carbonate-soluble and insoluble proteins, we observed that all b5 was found in the pellet 
fraction, after incubation both with buffer and with RRL (Figure 5). b5 behaved the same 
way as the integral protein calnexin, and differently from the soluble protein PDI, which was 
found only in the supernatant fraction. This was also true in the condition b5-ER in buffer, 
which means that even when b5-ER is mistargeted to the MOM, it is fully integrated and not 
merely attached to the membrane of this organelle. In conclusion, despite the condition or 
the target organelle, b5 is always inserted into the lipid bilayer efficiently as an integral 
membrane protein. 
 
5. b5-ops, with an N-glycosylation site, behaves like the non-tagged protein, b5-
ER. 
 
To confirm the information obtained with immunofluorescence experiments with 
biochemical ones, we performed the same experiments using the recombinant protein b5-
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ops (construct 4 in Figure 1). This construct contains at the C-terminus a tag derived from 
the N-terminal sequence of bovine opsin; this tag contains a site for N-glycosylation, which 
allows the detection of translocation of the protein's C-terminus into the ER lumen, where 
the glycosylation is carried out by the enzyme oligosaccharyl-transferase. 
We first assessed the localisation of this protein by immunofluorescence, in two 
different experiments. The first one shows the co-localisation of b5-ops with the MOM 
marker, Mitochondrial Fission Factor (MFF). As can be seen in Figure 6A, in buffer b5-ops 
perfectly co-localised with MFF, meaning that it was localised to the MOM (upper panel). 
On the other hand, in RRL the protein showed an ER pattern and, indeed, there was almost 
no co-localisation with the MOM marker (bottom panel). 
To further demonstrate the ER targeting, we repeated the experiment using an ER 
marker for comparison (Figure 6B). In this case, the day before the cells were transfected 
with extended-Synaptotagmin-1 (E-Syt1-GFP, construct 9 in Figure 1). As expected, in RRL 
we observed co-localisation between b5-ops and E-Syt1-GFP, indicating its targeting to the 
ER (Figure 6B, bottom panel). Yet, as occurred with the non-tagged b5-ER, some co-
localisation with the MOM marker was also observed. Nevertheless, it is clear that in buffer, 
the co-localisation with Tom20 is almost complete (Figure 6B, upper panel). Thus, b5-ops 
requires cytosolic chaperones to reach the ER and, in the absence of cytosol, is mistargeted 
to the MOM, similarly to b5-ER. 
To demonstrate the insertion into the ER biochemically, at the end of the incubation of 
b5-ops with semi-intact cells, the cells were lysed and analysed by SDS-PAGE and WB (Fig. 7 
-see Methods). When the incubation was done with RRL, the western blot showed an 
additional band that migrated approximately 3 KDa higher than the one of b5 (∼20 KDa - 
Fig. 7A). This band corresponds to the glycosylated b5, as demonstrated by its sensitivity to 
Peptide-N-glycosidase F (PNGase F- Fig. 7C), and it indicates that the C-terminus of b5-ops 
was translocated into the ER lumen, where the glycosylation machinery resides (Figure 7A). 
The quantification of the percentage of protein glycosylated revealed that it was >25% in 
RRL, and that this value was significantly different from the 4% obtained in buffer (Figure 
7B). In this case, the efficiency of glycosylation reflects not only the quantity of b5 that 
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successfully reached the ER but also the capacity of the glycosylation machinery. It is possible 
that the amount of protein that we are adding to the cells is in excess compared to the 
saturation limit of the enzymes involved in this process. Moreover, the presence of an 
accessible, correctly-oriented glycosylation site, is an absolute requirement for an efficient 
glycosylation. 
Since b5-ER relies on energy-dependent factors to be targeted to the ER, we 
investigated this requirement for b5-ops with our biochemical assay. b5-ops was incubated 
with semi-intact cells and with RRL depleted of energy, and was analysed by SDS-PAGE 
followed by Western Blot. In conditions without energy, b5 was no longer glycosylated (or 
very weekly), as expected from the immunofluorescence results (Figure 7D). In addition, 
under this condition, the band of non-glycosylated b5 is weaker, demonstrating once again 
that with energy depletion there is less association of b5 with membranes. 
 
 
 
 
 
 
 
 
 
6. b5-ops import depends on time and cytosol concentration. 
 
 
To better characterise the system with semi-intact cells that we have developed, we 
first asked ourselves how dependent is b5 on the cytosolic factors present in the RRL. For 
that, we incubated b5-ops with different fractions of RRL diluted in KHM. As seen in the 
graph A of Figure 8, when RRL was diluted 1:2, glycosylation was almost as efficient as in the 
case of complete RRL; however, with the dilutions 1:4, 1:6 and 1:8, the glycosylation 
decreased dramatically, reaching 0% when incubated only with KHM. 
Then, we performed a time-course experiment, in which semi-intact cells incubated with 
b5-ops were collected at different time-points: 15, 30, 45 and 60 minutes (Figure 8B). The 
glycosylation of b5, in other words, the insertion of b5 into the ER, increased concomitantly 
with the incubation time, reaching its maximum after 1 hour of incubation with RRL. Finally, 
we were interested to know whether at the different time-points b5 had different 
localisations, for instance, if at early time-points was first wrongly inserted into the MOM 
and only after was relocated to the ER. This idea came from the work of Chen et al. (2014), 
who reported that a protein named ATAD1 (Msp1 in yeast), was able to extract mislocalised 
mitochondrial TA proteins, thus maintaining mitochondrial integrity. To do this, we used the 
5. Results 
 
 
 
70 
 
non-tagged protein, b5-ER, and we compared its localisation with markers of ER and of 
MOM, respectively RFP-KDEL and Tom20. After 5 and 15 minutes of incubation with RRL, 
b5-ER showed a dual localisation, both ER and MOM, as quantified by Mander’s co-
localisation coefficients (Figure 8C). At 30 minutes, the localisation to the MOM had reached 
a plateau, while the ER localisation continued to increase. Since the mitochondria-associated 
fluorescence never decreased, the results suggest that the MOM-localised fraction of b5-ER 
is not a precursor to the ER-targeted portion; rather, the results suggest that b5-ER is directly 
targeted to the ER in a relatively slow process. 
 
7. TRC40 pathway plays a minor role in b5-ops targeting. 
 
As described in the introduction, the main pathway for post-translation insertion of TA 
proteins into the ER is the TRC40 pathway (Stefanovic and Hegde, 2007). TRC40 is an ATPase 
that binds to hydrophobic TMDs of proteins and delivers them to the ER. Although it has 
been reported that cytochrome b5 does not need assistance for its insertion (Favaloro et al., 
2008; Brambillasca et al., 2006), an interaction of b5 with TRC40 has also been demonstrated 
(Colombo et al., 2009; Stefanovic and Hegde, 2007; Favaloro et al., 2010).  
We therefore wondered whether TRC40 had a role in the targeting of b5-ER. To study 
this pathway, we applied different approaches. First, we interfered with TRC40 taking 
advantage of the protein WRBcc, which acts as a decoy receptor. WRBcc corresponds to the 
coiled coil portion of WRB, and it is the binding site of TRC40-TA complex (Vilardi et al., 
2011). By adding WRBcc to our semi-intact system, it competes with resident WRB at the ER 
membrane, thus blocking the delivery of TRC40-TA complexes to its receptor. WRBcc wild-
type (WRBcc WT) or a mutant, inactive, version (WRBcc MUT) were expressed in bacteria 
and purified (see Methods and Figure 9A), incubated with b5-ops and RRL at a concentration 
of 5 µM and applied to semi-intact cells. The western blot revealed a weaker glycosylated 
band of b5 after incubation with WRBcc WT (Figure 9B). Quantification of the blots revealed 
that WRBcc caused a modest, but significant decrease of b5’s insertion into the ER, when 
compared to WRBcc MUT (graph in Fig. 9B). As positive control for the effect of WRBcc, we 
used another construct, syb2-ops (construct 7 in Figure 1A). This construct corresponds to 
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cytochrome b5 with the TMD of synaptobrevin-2, which is a bona fide substrate of TRC40. 
Since the TMD of this protein is highly hydrophobic, it was impossible to obtain the 
recombinant protein from bacteria in the absence of detergent, and so we performed this 
experiments doing in vitro translation of both syb2-ops and b5-ops TA proteins. We found 
that differently from b5, whose glycosylation was only slightly affected by the addition of 
WRBcc, syb2’s glycosylation was almost completely abolished (Figure 9C). Thus, while a 
great majority of b5 can still reach the ER when TRC40 is blocked, syb-2 certainly depends 
on this chaperone for its insertion also in semi-intact cells, in agreement with previous 
results in cell-free systems (Colombo et al., 2016). 
To further investigate the role of WRB/TRC40, we repeated the same experiments by 
siRNA-mediated silencing of WRB. The silencing was done for 48 hours with two different 
siRNA’s and the efficiency of silencing achieved was always high (Figure 10A). We first used 
scramble or siRNA transfected HeLa cells to investigate the localisation of recombinant b5-
ops by immunofluorescence. As seen in the Figure 10B, in both cases b5-ops showed an ER-
like structure, but, when WRB was silenced, the co-localisation of b5-ops with the MOM 
marker Tom20 was more evident (yellow in the merge image, bottom panel). 
Notwithstanding the values of co-localisation with mitochondria obtained after 
quantification were relatively similar (43% in scramble and 49% in silenced cells), from a 
statistical point of view this difference was significant (data not shown). 
The glycosylation of recombinant b5-ops in cells silenced for WRB (Figure 11C) was 
decreased by approximately 25%, in agreement with the results obtained with the WRBcc. 
This difference was again significant, when compared to the values of glycosylation obtained 
with scramble transfected cells. Once more, we performed in vitro translation to compare 
both b5-ops and syb2-ops. While b5’s insertion into the ER was weakly affected after 
silencing of WRB, syb-2 showed again a strong dependence on the TRC40 pathway, since its 
glycosylation was reduced by 60% (Figure 11D). The differences in syb2’s glycosylation 
between WRBcc addition and WRB knockdown, i.e., the less dramatic effect obtained in this 
last approach could be explained by the fact that, upon silencing, there is still some WRB 
available, which can perhaps be enough for the functioning of the TRC40 pathway. Hence, 
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the TRC40 pathway would be impaired, but not completely abolished; on the contrary, when 
the receptor is blocked by the WRBcc, the formation of complexes of TRC40-TA that cannot 
be delivered to the ER membrane would limit its insertion to a greater extent. 
An alternative way to investigate the involvement of TRC40 was by depleting TRC40 
from the RRL. An immunodepletion with anti-TRC40 antibodies and one with an unrelated 
IgG (mock depletion) were done in parallel. The depletion was checked by western blotting 
and, as shown in Figure 11A, the RRL was efficiently depleted. The TRC40 depleted lysate 
was then incubated with the recombinant b5-ops in semi-intact cells and the glycosylation 
was checked by western blotting. As shown in Fig. 11B and C, TRC40 depletion, like WRBcc 
and WRB silencing, had a modest effect on b5-ops glycosylation (~20% inhibition), although 
the difference with the control did not reach statistical significance. 
Finally, the last experiment that was done to characterise the role of TRC40, although 
indirectly, was carried out by investigating the role of the chaperone SGTA in the targeting 
of b5 to the ER. As explained before in the introduction, SGTA is a chaperone that shields TA 
proteins from the aqueous cytosol, by recognising and binding to the hydrophobic exposed 
regions. It was demonstrated that SGTA can act as a bridge, by connecting substrates from 
the ribosomal exit to the Bag6 complex, the pre-targeting complex of TRC40 pathway. 
Furthermore, a recent structure-based study of the Bag6 complex suggests that SGTA can 
also directly hand off TA proteins to TRC40 (Roberts et al., 2015). If SGTA does so for 
cytochrome b5, after the knockdown of this chaperone, we would expect to see less ER 
targeting and perhaps an increased targeting to the MOM. 
Since SGTA is a cytosolic chaperone, we could not apply our import assay with semi-
intact cells by adding RRL, which contains SGTA. So, to perform this experiment we applied 
a microinjection protocol in cells silenced for SGTA (Fig. 12A). Microinjection can be 
considered an acute transient transfection and, in this case, consisted in the injection of the 
recombinant b5-ER into the cytoplasm of cultured cells, followed by fixation after 15 minutes 
(Figure 12B). By immunofluorescence analysis we saw no difference in b5-ER localisation in 
either 48 hours of scramble or SGTA siRNA transfected cells (Figure 12C). In both cases, b5-
ER displayed an ER-like structure and, indeed, the difference in the co-localisation with the 
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MOM between the two conditions was not significant (Figure 12D). Thus, b5-ER reaches the 
ER by one or more pathways not involving SGTA.  
In conclusion, with these different approaches we concluded that the involvement of 
the TRC40 pathway in the delivery of cytochrome b5 to the ER membrane is minor. Most 
likely, b5 can take advantage of this chaperone if available; but, if not, b5 can use one or 
more additional pathways and still reach the ER. 
 
8. The SND mediated pathway plays a minor role in b5-ops targeting. 
 
Recently, an SRP-independent targeting system was discovered in yeast and termed 
SND system (Aviram et al., 2016). This novel pathway involves the cytosolic component 
SND1, which binds to ribosomes and, subsequently, to its receptor in the ER membrane 
(comprising SND2 and SND3). To understand if the SND pathway may be involved in TA 
protein targeting, we silenced human SND2, the only mammalian orthologue described so 
far (Aviram et al., 2016). The silencing was done with four different siRNA’s for 72 hours and 
it was checked by western blotting (Figure 13A, upper panel). Then, after incubation of b5-
ops with RRL in semi-intact cells, the % of glycosylation was analysed (Figure 11A, bottom 
panel). Since the results showed a very similar extent of glycosylation in all siRNA’s tested 
(Figure 12A), we continue the experiments using only the SND2 siRNA#3. 
It was suggested that the three pathways, SRP, SND and TRC40, work in parallel to 
facilitate the ER targeting of proteins bearing TMDs in all possible relative positions (Aviram 
et al., 2016). Following this theory, we wondered what would happen to cytochrome b5 if 
both TRC40 and SND pathways were blocked. We therefore performed a double knockdown 
of SND2 and WRB. The silencing was done for 72 hours for SND2 and for 48 hours for WRB 
(Figure 12B). Confirming our previous observations, the individual knockdown of WRB 
decreased the percentage of b5’s glycosylation by ~25%, while SND2 silencing had a milder 
effect (~15% inhibition). When both pathways were blocked, the effect was, at most, 
additive (graph of Figure 12B). Thus, despite the fact that these two pathways may play a 
role in b5’s targeting, there are for sure other(s) pathway(s) involved, as more than 60% of 
the b5 protein is still able to be inserted into the ER in the absence of both of them. In 
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addition, since the effect obtained with the double knockdown tends to be additive, this 
suggests that these two pathways are independent.  
 
9. No evidence for an involvement of heat shock proteins.  
 
Another protein implicated in the targeting of b5 in vitro is Hsc70 (Abell et al., 2007; 
Rabu et al., 2008; Rabu et al., 2009). To test its potential role, we treated the RRL with a 
series of chemical inhibitors: MAL2-11B, DMT002220 and DMT003024 (Fewell at al., 2004). 
All of them inhibit the Hsp40-stimulated Hsp70 ATPase activity. We also evaluated the 
involvement of another chaperone, Hsp90, by treating cells with the antibiotic 
geldanamycin. Geldanamycin blocks the action of Hsp90, by binding to the unusual 
ADP/ATP-binding pocket of the protein.  
After RRL treatment with the described drugs, individually, the cells were permeabilised 
and then incubated with the recombinant b5-ops in RRL (see Methods). None of the 
treatments succeeded in blocking the targeting of b5 to the ER. An example for MAL2-11B, 
a molecule with improved chemical properties derived from MAL3-101 (Figure 14A) is 
shown in Figure 14B. The effect was compared with DMSO treatment, the solvent in which 
MAL2-11B was dissolved, but in some experiments a molecule with no Hsp70 ATPase activity 
inhibition, MAL3-51, was also used as control (data not shown). The quantification of b5’s 
glycosylation after Hsp70 inhibition was minor (<10%) and statistically non-significant when 
compared to DMSO (Figure 14B). The same was true for all the drugs tested.  
 
 
 
 
 
 
10. ES I treatment affects b5, but not syb2, insertion. 
 
 
The translocation of preprocecropin A, a short secretory protein, into ER derived 
microsomes is inhibited by the small molecule inhibitor eeyarestatin I (ES I) (Cross et al., 
2009; Johnson et al., 2012). ES I is a potent inhibitor of ERAD, targets the p97-associated and 
ataxin-3- dependent deubiquinating processes, and inhibits Sec61-mediated protein 
translocation at the ER (chemical structure in Figure 14C). Based on this, we decided to check 
the effect of this drug in b5’s targeting. Initially, we treated the RRL with 10 or 100 µM of ES 
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I, for 1 hour on ice; then, the recombinant b5-ops was added and incubated with semi-intact 
cells for 1 hour at 26 °C. We observed that the glycosylation of b5 was severely affected 
(Figure 14D). Even at 10 µM, ES I caused a 50% reduction of glycosylation (graph of Figure 
14D), an effect that was stronger than that obtained with any of the other treatments. We 
repeated the experiment by doing in vitro translation of b5-ops and syb2-ops and by treating 
the translation mixtures at the end with ES I. Surprisingly, we found that the dramatic effect 
of ES I on b5’s import, was not reproduced for syb2, which was glycosylated even more 
efficiently than under control conditions. This observation excluded the possibility that the 
drug was somehow interfering with the glycosylation machinery and not with the ER 
insertion. 
Given the substrate-specific effect of ES I, we were interested to know whether this 
effect was shared with other spontaneously inserted TA proteins, e.g., PTP1B. Since the 
glycosylated PTP1B migrates very close to the non-glycosylated portion, the analysis of the 
glycosylation of this TA protein was done with concanavalin beads (see Methods). In this 
way we could compare b5, PTP1B and syb2 after treatment with ES I. As it can be seen in 
Figure 15A, the glycosylated band (bound fraction) of both b5 and PTP1B was weaker after 
treatment with ES I, while the glycosylated band of syb2 remained unaltered compared with 
the bound fraction of control lysates. The quantification (Figure 15A on the right) revealed 
that b5 and PTP1B were affected almost in the same way, with an inhibition in the 
glycosylation varying from 35 to 45%. In contrast, syb2’s glycosylation was higher compared 
to control DMSO.  
An analogue of ES I with a related structure, ES35 (Figure 14C), which is biologically 
inactive (Cross et al., 2009), was used to decipher if the action of ES I on TA protein insertion 
correlates to its known biological activity. The effect of ES35 did not differ from the one of 
the vector (DMSO) and, as expected, differed from the one with ES I (Figure 15B). What is 
important to note is that, in all cases in which we analised the effect of ES I, the inhibition 
observed was not due to an increase of the percentage of non-glycosylated band (that we 
could expect since ES I is an ERAD inhibitor), but to a decrease in the glycosylated band (i.e., 
in the inserted protein).  
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As said before, ES I inhibits p97-associated deubiquination. Misfolded proteins are 
ubiquitinated and extracted from the membranes upon ATP hydrolysis of p97 and 
subsequently targeted to the proteasome for degradation. To explore if the effects of ES I 
where mediated through p97, we selected a potent and specific inhibitor of this ATPase, 
DBeQ (N2,N4-dibenzylquinazoline-2,4-diamine). DBeQ inhibits the degradation of 
ubiquitinated proteins, the ERAD pathway, and autophagosome maturation (Chapman et 
al., 2015). Under the same conditions, the RRL was treated with this drug and the effect on 
b5-ops glycosylation was analysed. As easily observed by the western blot and the respective 
quantification (Figure 15C), the glycosylation of b5-ops remained unaltered. Thus, the 
effects of ES I in reducing the integration of b5-ops in the ER are not mediated by p97 ATPase 
inhibition. 
 
11. Sec61 knockdown affects b5, but not syb2, insertion. 
 
 
Lastly, since it is known ES I inhibits Sec61-mediated protein translocation at the ER, we 
decided to test the unlikely role of Sec61 translocon in the post-translational insertion of b5 
into the ER. We silenced the α subunit of Sec61 with a double transfection for 72 hours and 
we verified that only the siRNA#2 was efficient (Figure 16A). First, we used Sec61 silenced 
cells to check the glycosylation of recombinant b5-ops (Figure 16B). We found a decrease in 
b5’s insertion of approximately 25% (close statistical significance, p = 0,052). When the 
Sec61 knockdown was examined in in vitro translated b5-ops and syb2-ops proteins, we 
discovered that its effect was specific for b5 and not for syb2, which was almost not affected 
(Figure 16C). This goes in line with the results obtained after treatment with ES I and suggest 
that ES I affects b5’s insertion by inhibiting the Sec61 translocon. Finally, we performed an 
experiment doing a double knockdown of Sec61 and WRB. We found that the inhibition of 
b5’s glycosylation is the same whether Sec61 and WRB are silenced individually or together 
(Figure 16D). This might mean that they act in the same pathway, i.e., that TRC40 could 
deliver b5 to the ER membrane via Sec61 translocon. Alternatively, compensating pathways 
are activated in the silenced cells (see Discussion).  
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Figure 1: Constructs and protocol used for import assays. 
 
A) Schematic representation of the constructs used in this work. The grey box shows the 
promoter of each plasmid and the blue box in constructs 2,3 and 4 the coding region for 
GST. The black rectangle represents the TMD of cyt b5, which is the same in constructs 1 to 
5, and the red rectangle represents the opsin tag containing a N-glycosylation site. Construct 
3, b5-RR, differs to b5-ER only in the last residues at the C-terminal (depicted as a dashed 
rectangle). Construct 7, Syb2-ops, contains the sequence of b5 but the TMD of 
synaptobrevin 2 (green rectangle). Construct 6, which codes for PTP1B (yellow, with TMD in 
blue), also contains the C-terminal opsin epitope. Constructs 8 and 9, under the CMV 
promoter, were used as ER markers and were obtained from Erik Snapp and Pietro De 
Camilli, respectively. Construct 1 (obtained from Fabio Vilardi and used to block the TRC40 
pathway), and construct 11 (corresponding to a mutant version of construct 10, from 
Stephen High) code for Maltose Binding Protein (light green boxes) fusion proteins and, like 
the pGEX constructs, are under an IPTG-inducible promoter. 
B) Scheme of the protocol used for import assays. Adherent cells were permeabilised with 
digitonin, 5 minutes at 26°C, to empty their cytosolic content; then, the in vitro translated 
or the recombinant protein was incubated with the cells together with rabbit reticulocyte 
lysate (RRL) or buffer (KHM), for 1 h at 26°C. At the end, the cells were washed and analysed 
by western blot or immunofluorescence. 
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Figure 2: Purification of recombinant proteins. 
CBB-stained SDS-polyacrylamide gels showing the purification of b5-ER (A), b5-RR (B) and 
b5-ops (C) proteins. All three were expressed in BL21 bacteria as GST fusion proteins. After 
lysis of the bacteria, the soluble fraction was incubated on a rotating wheel with GSH-
Sepharose 4B beads (GSB4 resin). Between the sequence of the GST and the sequence of b5 
there is a cleavage site for thrombin, which results in the release of b5 protein by the enzyme 
(see Methods). The samples containing the soluble, insoluble and unbound fractions, were 
loaded in 12-fold excess over the total lysate; the lanes of bound to resin, eluate, wash and 
resin after thrombin were loaded in 16-fold excess over the soluble fraction, and are thus 
comparable each other. Note that most of the fusion protein is insoluble, but sufficient 
amounts can be purified from the soluble fraction. All of the soluble fusion protein binds to 
the resin and can be eluted by thrombin treatment. In each panel, the arrow, asterisk, and 
arrowhead indicate the fusion protein, cleaved GST, and cleaved recombinant b5, 
respectively.  Note that the cleaved GST remains associated with the resin. 
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Figure 3: Localisation of recombinant b5 forms in semi-intact cells. 
The cells were transfected with RFP-KDEL (ER marker, in red) and, 24 hours thereafter, 
permeabilised with digitonin and incubated with recombinant b5-RR (A) or b5-ER (B), either 
in buffer (KHM), RRL, or energy-depleted RRL, as indicated. The cells were processed for 
immunofluorescence with anti-b5 antibody (green) and anti-Tom20 (MOM marker, in blue).  
In panel B, the arrows indicate the nuclear envelope, diagnostic for ER localisation (inset: 2x 
magnification). The cumulative results of quantification of cells like the one of this figure are 
shown in Figure 5. Single sections acquired with the LSM Meta microscope are shown. Scale 
bar = 5 µm. 
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Figure 4: Quantitative analysis of the localisation of b5-ER and b5-RR under three 
different conditions (buffer, RRL and RRL with energy depletion). 
A) Localisation of b5-RR (white) and b5-ER (grey) to the MOM. This corresponds to the 
percentage of b5 protein that co-localises with the MOM marker, Tom20. B) Localisation of 
b5-RR (white) and b5-ER (grey) to the ER. This corresponds to the percentage of b5 protein 
that co-localises with the ER marker, RFP-KDEL. In (A) and (B), co-localisation of cytochrome 
b5 with mitochondria or ER markers was quantified by Mander’s co-localisation coefficients 
(see Methods). Data presented are means ± SEM (number of cells analysed: b5-RR in KHM, 
22; b5-RR in RRL, 57; b5-RR in energy depleted RRL, 51; b5-ER in KHM, 33; b5-ER in RRL, 110; 
b5-ER in energy depleted RRL, 64). Statistical significance was assessed by one-way Anova 
followed by Bonferroni's post-test.  
C) Total cell-associated fluorescence intensity (in arbitrary units) of b5-RR and b5-ER after 
incubation in the presence of RRL and energy depleted RRL. Data presented are means ± 
SEM. The significance for plus vs minus energy for each construct was assessed by Student's 
t test (number of cells analysed: b5-RR in RRL, 22; b5-RR in energy depleted RRL, 48; b5-ER 
in RRL, 60; b5-ER in energy depleted RRL, 80). 
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Figure 5: Analysis of b5 integration into the lipid bilayer by the carbonate extraction 
method. 
After incubation of b5-ER (top) or b5-RR (bottom) with semi-intact cells, as in Figs 3-5, cells 
were homogenised and treated with Na2CO3 as described in the Methods. Equal aliquots of 
total sample (T), supernatants (S), and pellets (P) were analysed by western blot. Resistance 
to extraction of b5-ER (upper image) and b5-RR (bottom image) demonstrates that b5 is 
integrated into membranes after incubation either in buffer or in RRL. Calnexin and PDI were 
analysed as controls for an integral membrane protein and a soluble lumenal ER protein, 
respectively.  
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Figure 6: Localisation of b5 -ops in semi-intact cells. 
Recombinant b5-ops was incubated with semi-intact cells in buffer (KHM) or RRL, as 
indicated. Panel A illustrates the lack of co-localisation of the construct with the MOM 
marker and its marked staining of the nuclear envelope, indicative of ER localisation. Panel 
B confirms the ER localisation of the construct by comparison with a transfected ER maker 
(extended Synaptotagmin 1). In this case, the cells were transfected, and semi-
permeabilised 24 h thereafter. A: cells were stained with anti-opsin mAb and anti-MFF 
(MOM marker) polyclonal antibodies, as indicated. B: cells were stained with anti-Tom-20 
mAb and anti-b5 polyclonal antibodies, as indicated. In A and B, single sections were 
acquired with a Confocal Spinning Disk LCI Ultraview system. Scale bar = 10 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Figures and legends 
 
 
 
89 
 
 
 
 
Figure 7: Biochemical analysis of b5-ops. 
A) Representative western blot of b5-ops after incubation with semi-intact cells in the 
presence of buffer or RRL. Equal amounts of cell lysates were loaded and the transferred 
proteins were immunoprobed with anti-opsin mAb. The band corresponding to the 
glycosylated b5 is indicated (b5 glyc).  
B) Quantification of the percentage of glycosylation of b5-ops in buffer and RRL (related to 
Figure A). Data are presented as mean ± SEM (n=5). 
C) The cells were subjected to immunoprecipitation with anti-opsin antibody; the 
immunoprecipitates were divided in two, and one part was digested with PNGase F (see 
Methods) before SDS-PAGE/WB analysis as indicated. 
D) Representative western blot of b5-ops in semi-intact cells incubated with RRL or RRL 
depleted of energy. Equal amounts of cell lysates were loaded and the transferred proteins 
were immunoprobed with anti-opsin mAb. The band corresponding to the glycosylated b5 
is indicated (b5 glyc). 
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Figure 8: Time course and cytosol-dependence of b5-ops import. 
A) The percentage of glycosylation of b5 depends on the RRL concentration. Cells were 
incubated for 1h with RRL under standard conditions, and with RRL diluted with KHM as 
indicated.  
B) The percentage of glycosylation of b5 increases concomitantly with the time of incubation 
of the protein with RRL at 26°C. Cells were lysed at the indicated time points and analysed 
by SDS-PAGE/WB.  
C) Time course of localisation of b5-ER in RRL. Cells were fixed at the indicated time points 
and analysed by immunofluorescence. ER localisation was accessed with RFP-KDEL and 
MOM localisation with Tom20. 
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Figure 9:  Effect of WRBcc on ER insertion of b5 -ops and Syb2-ops. 
A) CBB-stained gel showing the purification of MBP-WRBcc. MBP-WRBcc and MBP-WRBcc 
MUT were purified from the soluble fraction of an IPTG induced BL21 sonicate and incubated 
with amylose resin (gel on the left). Most of the protein is soluble (lanes 1-3), but, under our 
conditions, not all of the fusion protein binds to the amylose resin (lanes 5,6). Nearly all the 
bound protein can be eluted with maltose (lanes 6,7). WRBcc MUT behaved in the same way 
as the wild-type protein (not shown). In both MBP-WRBcc wild-type and MUT, incubation 
with TEV protease allows the cleavage of WRBcc (MW=9 KDa) from MBP (MW=42.5 KDa) 
(gel on the right). Volumes loaded are comparable in all lanes. 
B) Representative western blot of recombinant b5 -ops incubated with semi-intact cells in 
the presence of RRL pre-treated with 5 µM WRBcc MUT or WRBcc WT. Equal amounts of 
cell lysate were loaded and the transferred proteins were immunoprobed with anti-opsin 
mAb. The band corresponding to the glycosylated b5-ops is indicated (b5 glyc). 
Quantification of the percentage of glycosylation of b5-ops is shown in the graph below. 
Data are presented as means ± SEM (n= 3).  
C) Representative western blot of in vitro translated b5-ops and syb2-ops incubated with 
semi-intact cells in the presence of RRL treated with 5 µM WRBcc MUT or WRBcc WT. Equal 
amounts of cell lysates were loaded, and the transferred proteins were immunoprobed with 
anti-opsin mAb. Quantification of the percentage of glycosylation of b5-ops and syb2-ops is 
shown in the graph below.  
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Figure 10: Effect of WRB knockdown on b5-ops insertion. 
A) Lysates were prepared 48 hours after transfection with WRB silencing (siRNA1 and 
siRNA2) or scrambled paired oligonucleotides (scr). Equal aliquots were analysed by western 
blotting. Calnexin was also determined and was used for normalisation. The percentage of 
WRB after silencing is indicated. 
B) Localisation of b5-ops in semi-intact cells after WRB knockdown. RRL and recombinant 
b5-ops were added to permeabilised cells transfected with scramble (upper panel) or WRB 
siRNA#2 (bottom panel). The cells were processed for immunofluorescence with anti-opsin 
antibody (green) and anti-Tom20 (MOM marker, in red).  Images were acquired with the 
Ultraview Confocal Spinning Disk LCI (Perkin Elmer). Single sections are shown. Scale bar = 
10 µm. 
C) Representative western blot analysing recombinant b5-ops glycosylation in semi-intact 
cells silenced for WRB. Equal amounts of cell extracts were loaded, and the transferred 
proteins were immunoprobed with anti-opsin mAbs. The band corresponding to 
glycosylated b5-ER is indicated (b5 glyc). Quantification of the percentage of glycosylation 
(for WRB siRNA#2) is shown in the graph below. Data are presented as mean ± SEM; 
statistical significance was assessed by Student's paired t test (n = 4). 
D) Western blot of in vitro translated b5-ops and syb2-ops in semi-intact cells silenced for 
WRB. Equal amounts of cell extracts were probed with anti-opsin mAbs. Quantification of 
the percentage of glycosylation (average of WRB siRNA#1 and siRNA#2) is shown in the 
graph below.  
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Figure 11: Effect of TRC40 depletion on b5-ops insertion. 
A) Western blot analysis of 1 and 2 µl of mock- or TRC40-depleted RRL, as indicated. The 
blots were probed with anti-TRC40 antibodies and developed by ECL. 
B) Representative western blot analysing recombinant b5-ops glycosylation in semi-intact 
cells incubated with ΔTRC40 RRL. Equal amounts of cell extract were immunoprobed with 
anti-opsin mAbs. The band corresponding to glycosylated b5-ops is indicated (b5 glyc).  
C) Quantification of the percentage of b5-ops glycosylation in ΔTRC40 RRL, compared to 
control (mock depletion) (related to B). Data are presented as mean ± SEM (n=3).  
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Figure 12: Lack of effect of SGTA knockdown on b5-ER localisation. 
A) Lysates were prepared 48 hours after transfection with SGTA silencing (SGTA siRNA#1) or 
scrambled paired oligonucleotides (scramble). Equal aliquots were analysed by western 
blotting and normalised to calnexin. The percentage of SGTA after silencing is indicated. 
B) Scheme of the protocol used for microinjection. Cells transfected with scramble or SGTA 
siRNA#1 were microinjected with purified recombinant b5-ER, and then fixed after 15 
minutes.  
C) Localisation of microinjected b5-ER in cells silenced for SGTA. The cells were processed 
for immunofluorescence with anti-b5 antibody (green) and anti-Tom20 (MOM marker, in 
blue). Single section, acquired with the Ultraview Confocal Spinning Disk are shown. Scale 
bar = 10 µm. 
D) Quantitative analysis of the co-localisation of microinjected b5-ER with the MOM marker, 
Tom20, in scramble and SGTA silenced cells. Co-localisation of b5-ER with mitochondria was 
quantified by Mander’s co-localisation coefficients (see Methods).  Data presented are mean 
± SEM (scramble, n = 20   cells; SGTA siRNA#1, n = 22 cells). 
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Figure 13: Effect of SND2 knockdown on insertion of b5-ops. 
A) Lysates were prepared 72 hours after transfection with SND2 silencing (siRNA#1, 
siRNA#2, siRNA#3, siRNA#4) or scrambled paired oligonucleotides (scramble). Equal 
amounts of protein were analysed by WB. The percentage of SND2 after silencing 
(normalised to Calnexin, shown above) is indicated under the lanes. The bottom panel shows 
a western blot analysing recombinant b5-ops glycosylation in semi-intact cells silenced for 
SND2 (siRNA#1, siRNA#2, siRNA#3, siRNA#4) probed with anti-opsin mAbs. The band 
corresponding to glycosylated b5-ER is indicated (b5 glyc). Quantification of the percentage 
of glycosylation is shown in the graph on the right.  
B) SND2 and WRB double knockdown. Left, upper: WB analysis of recombinant b5-ops 
glycosylation in semi-intact cells silenced for WRB (WRB siRNA#2), SND2 (SND2 siRNA#3), 
and WRB+Snd2 (WRB siRNA#2 + SND2 siRNA#3), as indicated. Left, bottom: analysis of 
degree of silencing of WRB or SND2, when silenced singly (left) or together (right). The graph 
on the right shows the quantification of the percentage of glycosylation of b5-ops under the 
different conditions, each one normalised to scramble siRNA. Data are presented as mean ± 
half-range (n=2). 
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Figure 14: Treatment of RRL with drugs and its effect on ER insertion of b5-ops. 
A) Chemical structures of the Hsp70 inhibitor MAL2-11B, derived from MAL3-101 (Wright 
et al., 2009). 
B) Representative western blot of recombinant b5-ops incubated with semi-intact cells in 
the presence of RRL pre-treated with 100 µM MAL2-11B. Treatment with an equal volume 
of DMSO was used as control. The transferred proteins were probed with anti-opsin mAbs. 
The band corresponding to the glycosylated b5-ops is indicated (b5 glyc). Quantification of 
the percentage of glycosylation of b5-ops, compared to control (DMSO) is shown in the 
graph on the right. Data are presented as mean ± SEM (n = 5). 
C) Chemical structures of ES I and its inactive analogue, ES35 (Cross et al., 2009). 
D) Representative western blot of recombinant b5-ops incubated with semi-intact cells in 
the presence of RRL pre-treated with 10 or 100 µM ES I. Treatment with an equal volume of 
DMSO was used as control. The transferred proteins were probed with anti-opsin mAbs (gel 
on the left). The band corresponding to the glycosylated b5-ops is indicated (b5 glyc). 
Quantification of the percentage of glycosylation of b5-ops, normalised to control (DMSO) 
is shown in the graph below. Statistical significance was assessed by Student's paired t test. 
Data are presented as mean ± SEM (n = 4). 
E) Western blot of in vitro translated proteins, b5-ops and syb2-ops, which were treated 
with 100 µM of ES I after translation and then incubated with semi-intact cells. 
Quantification of the percentage of glycosylation of the two proteins, normalised to control 
(DMSO) is shown in the graph below. Drug treatment affects b5, but not Syb2, insertion. 
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Figure 15: Effect of ES I on the ER insertion of TA proteins. 
A)  In vitro translated 35S-radiolabeled, b5-ops, syb2-ops or PTP1B-ops were treated with 20 
µM ES I after translation, and then incubated with semi-intact cells. Treatment with an equal 
volume of DMSO was used as control. Cell extracts were exposed to Concanavalin A beads, 
and equal aliquots of the bound and unbound fractions were loaded (see methods). 50% of 
the input sample was also loaded. The band corresponding to the glycosylated form of each 
protein is indicated (b5-glyc, PTP1B-glyc and syb2-glyc). Quantification of the percentage of 
glycosylation, normalised to control (DMSO) is shown in the graph on the right. Band 
intensities were quantified with Image Quant TL 7.0 software. 
B)   Western blot of recombinant b5-ops incubated with semi-intact cells in the presence of 
RRL pre-treated with 20 µM ES I or with its inactive analogue, ES35. Treatment with an equal 
volume of DMSO was used as control. The transferred proteins were probed with anti-opsin 
mAb. The band corresponding to glycosylated b5-ops is indicated (b5 glyc). Quantification 
of the percentage of glycosylation of b5-ops, normalised to control (DMSO) is shown in the 
graph below.  
C) Western blot of recombinant b5-ops incubated with semi-intact cells in the presence of 
RRL pre-treated with 20 µM of DBeQ, a p97 ATPase inhibitor. Treatment with an equal 
volume of DMSO was used as control. The transferred proteins were probed with anti-opsin 
mAbs. The band corresponding to the glycosylated of b5-ops is indicated (b5 glyc). 
Quantification of the percentage of glycosylation of b5-ops, normalised to control (DMSO) 
is shown in the graph below.  
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Figure 16: Effect of Sec61 knockdown on the ER insertion of TA proteins. 
A) Lysates were prepared 72 hours after a double transfection (at 24 and 48 hours) with 
Sec61 silencing (siRNA#1: SEC61A1/SEC61A2 and siRNA#2: SEC61A1) or scrambled paired 
oligonucleotides (scramble). Equal amounts of protein were analysed by western blotting. 
The percentage of Sec61 after silencing is indicated. 
B) Representative western blot of recombinant b5-ops after incubation with semi-intact 
cells silenced for Sec61 (Sec61 siRNA#1 and Sec61 siRNA#2) in the presence of untreated 
RRL. The transferred proteins were probed with anti-opsin mAbs. The band corresponding 
to glycosylated b5-ops is indicated (b5 glyc). Quantification of the percentage of 
glycosylation of b5-ops, normalised to control (scramble) is shown in the graph on the right 
(mean ± SEM, n = 4).  
C) Representative western blot of in vitro translated b5-ops and syb2-ops in semi-intact cells 
silenced for Sec61. The transferred proteins were probed with anti-opsin mAbs. 
Quantification of the percentage of glycosylation for Sec61 siRNA#2 knockdown, normalised 
to scramble, is shown in the graph below. (mean ± SEM, n = 3). 
D) Sec61 and WRB double knockdown. Upper: WB of recombinant b5-ops incubated with 
semi-intact cells silenced for WRB (WRB siRNA#2), Sec61 (Sec61 siRNA#2), and WRB+Sec61 
(WRB siRNA#2 + Sec61 siRNA#2), as indicated. The transferred proteins were probed with 
anti-opsin mAbs. The band corresponding to glycosylated b5-ops is indicated (b5 glyc). 
Middle: analysis of degree of silencing of Sec62 or WRB, when silenced singly (left) or 
together (right). The efficiency of silencing of both WRB and Sec61, normalised to calnexin, 
is shown. Bottom: Quantification of the percentage of glycosylation of b5-ops, normalised 
to scramble, under the indicated conditions. 
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Although the past few years have seen a surge of interest in the biogenesis of TA 
proteins and a consequent impressive increase of information, especially on the TRC/GET 
pathway (see (Borgese N., 2015) for a recent review), many aspects of the processes by 
which newly synthesized TA substrates are delivered to their target membrane are still 
mysterious. Given the physiological importance of many members of this class of membrane 
proteins, for example as regulators of apoptosis or of vesicular transport and exocytosis, the 
complete elucidation of the pathways governing their targeting and biogenesis is of 
paramount importance. Notably, these biogenetic pathways could represent novel 
pharmacological targets, e.g., by altering the membrane insertion of members of the Bcl-2 
family in cancer cells. An example of a pharmacological approach targeted to protein 
biogenesis/trafficking is offered by the so-called cotransins, which specifically interfere with 
the delivery to the ER lumen of a small number of secretory proteins (Garrison et al., 2005).  
One gap in our knowledge of TA protein targeting is the comprehension of pathways 
additional or alternative to the one mediated by TRC40. Indeed, although cell-free 
experiments have highlighted the importance of the TRC/GET pathway, in vivo or in cellula 
studies have revealed that alternative mechanisms may guarantee the delivery of many TA 
substrates to the ER in the absence of a functional GET pathway (Cui et al., 2015; Norlin et 
al., 2016). To investigate possible alternative pathways, I chose as model cytochrome b5, a 
protein that in cell-free systems spontaneously inserts into liposomes and into ER-derived 
microsomes in the absence of any cytosolic factor (Brambillasca et al., 2005; Colombo et al., 
2009).  
Two forms of b5 exist, which are each specifically targeted either to the ER or to the 
MOM (D'Arrigo et al., 1993). Characterisation of the targeting signals of the two isoforms 
led to the conclusion that the targeting information was in the C-terminal tail (De Silvestris 
et al., 1995); further research demonstrated that substitution of the last seven polar 
residues of b5-ER with two arginines (to obtain the protein b5-RR) was sufficient to reroute 
the protein to the MOM (Borgese et al., 2001). Although b5-RR is very precisely targeted to 
the MOM in vivo, in a cell-free system it efficiently inserts into the ER. Likewise, b5-ER, as 
mentioned above, can insert into protein-free liposomes, provided that they have low 
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cholesterol content. Each of the two proteins, when microinjected into the cytoplasm of 
cultured cells, inserts into its cognate organelle, indicating that the protein itself contains 
the information for correct post-translational targeting (unpublished). The mysterious 
pathways followed in vivo to achieve precise subcellular localisation of the two b5 forms 
have been the subject of my thesis research.  
Given the distinct differences in the in cellula and cell-free behaviour of the two b5 
forms, it was clear that not much information in addition to what is already known could be 
obtained from classical cell-free systems. I therefore decided to utilise a system that can be 
considered intermediate between cell-free and in cellula, consisting of semi-permeabilised 
cells; the plasma membrane of these cells are made permeable to macromolecules by 
treatment with low concentrations of digitonin, but the intracellular membranes remain 
intact (Wilson and Bulleid, 2000; Setoguchi et al., 2006). With this system, it is possible to 
replace the endogenous cytosol with cytosol from an exogenous source manipulated as 
desired, e.g., by removing or adding components. Compared to cell-free systems, these cells 
present the advantage of having all their endogenous organelles in the correct spatial 
relationships.  In this system, it is also possible to carry out both biochemical and 
morphological assays. In my research, I combined the use of semi-permeabilised cells with 
silencing experiments, and also with microinjection. Using these approaches, I was able to 
obtain novel and unexpected information on the targeting pathways followed by the two b5 
forms, which I discuss in this section of my thesis. 
 
The MOM as default destination of TA proteins. 
 
 
Previous work from my laboratory has demonstrated that both forms of b5 can insert 
into protein-free liposomes, provided that they have a very low cholesterol content; the 
inclusion of cholesterol in a ratio to phospholipids as low as 0.1 (Brambillasca et al., 2005) 
nearly completely blocks b5 insertion. The negative effect of the sterol could explain why TA 
proteins don't insert into membranes of the secretory pathway downstream to the ER, as 
these have high cholesterol content well above the 0.1 threshold value (Holthuis and 
Menon, 2014).  This explanation leaves open, however, the mechanism by which TA proteins 
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discriminate between low cholesterol containing membranes, i.e., in metazoans and fungi 
the ER, the MOM and peroxisomes.   
Based on the data from my laboratory showing that both b5-ER and b5-RR can insert 
efficiently both into ER-derived microsomes and into protein-free liposomes, we expected 
that in semi-permeabilised cells, and in the absence of cytosol, both forms would be similarly 
promiscuous. We were therefore surprised to observe that, in buffer alone, both b5 forms 
quite specifically targeted the MOM and were apparently completely excluded from the ER. 
The addition of cytosol and a source of energy, while not affecting the mitochondrial 
localisation of b5-RR, rerouted b5-ER to its correct destination.  These results indicate that, 
although in cell-free systems both b5 forms can insert into ER membranes, when faced with 
a choice, and in the absence of cytosolic factors, the MOM is the preferred destination for 
both of them. It may be that translocation of the C-terminus of TA proteins across the MOM 
is more rapid than across the ER; one can imagine that initially the TA substrate samples 
different bilayers, but that once its C-terminus is translocated, its localisation is irreversibly 
determined.  In the absence of cytosol, the MOM might win the competition on a kinetic 
basis, in that translocation across its bilayer could be more rapid than across the bilayer of 
other organelles. Instead, in the presence of cytosol, targeting factors that do not recognise 
the b5-RR form, would capture b5-ER, preventing it from inserting into the MOM and 
allowing its insertion into the ER instead.  It must be mentioned that the insertion of TA 
proteins in buffer alone is possible only for those with moderately hydrophobic TMDs; those 
with more hydrophobic TMDs (like synaptobrevin 2) are insoluble in the absence of 
chaperones, and therefore not amenable to targeting studies under buffer-only conditions. 
Previous studies have led to the idea that specific chaperones are required to route TA 
proteins to the ER and to peroxisomes, and that the MOM represents the default destination 
of TA proteins, i.e., the membrane into which they insert in the absence of interaction with 
specific targeting chaperones. This idea is based on a number of observations: (i) in yeast, a 
number of GET substrates are partially localised to mitochondria in ΔGET strains (Schuldiner 
et al., 2008); (ii) many MOM TA proteins have moderately hydrophobic TMDs, and can 
spontaneously insert into liposomes (Kemper et al., 2008); this feature keeps them from 
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interacting with Sgt2 and from the subsequent delivery to Get3. Indeed, increasing the 
hydrophobicity of a MOM TA protein (Fis1) resulted in its interaction with components of 
the GET pathway (Wang et al., 2010); (iii) no cytosolic nor MOM protein have so far been 
identified as components of a pathway for MOM delivery (Setoguchi et al., 2006; Krumpe et 
al., 2012); iv) similarly, the Pex19-dependent targeting of peroxisomal TA proteins depends 
on an excess of positively charged residues in the tail region; the feature of a positively 
charged tail region is shared by MOM proteins, but the amount of positive charge is more 
marked in peroxisomal substrates and required for delivery to the peroxisome; reduction of 
this charge results in mislocalisation to the MOM (Yagita et al., 2013).   
Although the work described in the previous paragraph, taken together, did suggest 
that the MOM could be a default destination, a clear-cut result like the one presented in this 
thesis had not yet been obtained. My results give strong support to the hypothesis of the 
MOM as default destination, in that I show that in the absence of cytosol, an ER TA protein 
is dramatically rerouted to mitochondria. This result raises two questions: (i) what is the 
feature of the MOM that favours it as destination of TA proteins over other intracellular 
membranes; and (ii) what is the identity of the molecular chaperones required for the ER 
targeting of b5-ER? 
Concerning the first question, previous studies have excluded the participation of the 
TOM machinery ((Setoguchi et al., 2006; Kemper et al., 2008, Krumpe et al., 2012) see 
introduction). Furthermore, treatment of semi-permeabilised cells with proteolytic 
enzymes, resulting in the digestion of proteins exposed on the MOM surface, did not affect 
the targeting of investigated TA substrates (Bak, Bcl-XL, and Omp25). On the other hand, it 
has been suggested that the low sterol content of the MOM may underlie its capacity to 
integrate TA proteins (Krumpe et al., 2012). While this hypothesis may be valid for yeast 
cells, in which the MOM does appear to have significantly lower sterol content than the ER 
membrane (Zinser et al., 1991; Schneiter et al., 1999), in mammals, the limited number of 
studies have indicated that the sterol content of the MOM and the ER are quite similar 
(Colbeau et al., 1971), or actually higher in the MOM than in the ER (Wibo et al., 1981). Thus, 
at least in mammals, the permissivity of the MOM must depend on a factor different from 
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sterol content: either on an embedded protein not accessible to proteases on the cytosolic 
side of the membrane, or on differences in composition of lipids other than sterols. As a 
possible candidate, I consider cardiolipin, a lipid exclusive to mitochondria, present mainly 
on the inner mitochondrial membrane but also in lower amounts on the MOM, whereas it 
is particularly enriched at contact sites between the inner and outer membranes (Hovius et 
al., 1990; Lutter et al., 2000). So far, however, my attempts to reveal alterations in MOM TA 
protein localisation in cardiolipin synthase silenced cells have been unsuccessful (result not 
shown in this thesis).  
The second question (identity of molecular chaperones required for the ER targeting of 
b5-ER) is addressed in the following section of this Discussion. 
 
Molecular chaperones involved in the ER insertion of b5-ER. 
 
In cell-free systems it has been amply demonstrated that b5 insertion into ER-derived 
microsomes is independent from the TRC40 pathway: immunodepletion of TRC40 from the 
RRL, while strongly inhibiting insertion of some substrates (e.g., Synaptobrevin-2 (Colombo 
et al., 2009); Sec61β (Rabu et al., 2009)), is completely ineffective on b5 insertion (Colombo 
et al., 2009); furthermore, inclusion in post-translational insertion assays of WRBcc, which 
inhibits TRC40-mediated targeting by acting as decoy receptor (Vilardi et al., 2011), is 
ineffective on b5 insertion (Colombo et al., 2016). Nevertheless, since b5's behaviour in cell-
free assays does not reflect its targeting behaviour in cellula, I considered it likely that the 
TRC40 pathway could play an important role in its discrimination between the ER and the 
MOM in vivo, and in semi-intact cells in the presence of cytosol.  This supposition was 
supported both by demonstration of the energy dependence of the targeting phenomenon 
(Figure 3), and by the previous observation that b5-ER does weakly interact with TRC40, as 
assessed by pulldown experiments (Colombo et al., 2009).  I therefore put a lot of effort into 
analysing the effect of interference with the TRC40 pathway on b5 integration into the ER in 
my system.  
I investigated a possible involvement of the TRC40 pathway in semi-permeabilised cells 
by three different approaches: (i) inclusion of WRBcc in the assay; (ii) the use of WRB-
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silenced cells in the assay; (iii) immunodepletion of TRC40 from the RRL. Since small 
differences in the intracellular distribution of b5-ER would have been difficult to assess 
quantitatively by IF, in all three of these approaches, I used glycosylation of b5-ops as 
reporter for ER insertion.  The results showed, that differently from the previous 
observations in cell-free systems, interference with the TRC40 pathway did diminish ER 
targeting of our substrate, however, this effect was partial (20-30%), and more marked for 
the recombinant protein than for the in vitro translated product. As positive control, I also 
analysed the effect of the treatments on the insertion of Syb2-ops, and found, as expected, 
near complete inhibition by WRBcc and 60% inhibition by WRB silencing. I also investigated 
the possible effect of the first member of the TRC40 pathway, SGTA (see Introduction), by 
microinjecting recombinant b5 into cells with downregulated SGTA and then analysing the 
microinjected cells by IF; by this approach I did not detect any difference between SGTA-
silenced and control cells. The role of SGTA remains, however, to be further investigated, 
since, as mentioned above, small differences in subcellular localisation of b5 might not be 
detected by IF.  From my results, I can conclude that the TRC40 pathway represents a 
delivery route to the ER for b5; however, the results also indicate that additional pathways 
must be available to this substrate, as the majority of the protein in any case was able to 
reach its correct destination in the absence of a functional TRC40 pathway.  
In search of these additional pathways, I investigated a possible involvement of Hsc70, 
the inhibition of which, in cell-free systems, was found to interfere with b5 insertion (Rabu 
et al., 2008). To this end, we applied a number of small molecule inhibitors of Hsc70, 
pyrimidone-peptoid compounds derived from MAL3-101, with different mechanisms of 
action (Wright et al., 2008). MAL2-11B and DMT003024 are both potent inhibitors of the 
Hsp40-stimulated Hsp70 ATPase activity, while DMT002220 interferes with both 
endogenous and Hsp40-stimulated Hsp70 ATPase activities. However, we found no effect of 
any of these inhibitors. The observed effects in the cell-free system might be indirect, due 
to aggregation of other Hsc70 clients, which could lead to non-specific co-aggregation of the 
in vitro synthesized b5 product. Thus, while Hsc70 may aid solubilisation of newly 
synthesised b5, it appears that the protein can faithfully target the ER in the absence of the 
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function of this chaperone. Likewise, inhibition of another important cytosolic chaperone, 
Hsp90, was also without effect on b5-ops glycosylation. 
Another pathway that I probed is the recently described SND pathway (Ast et al., 2013; 
Aviram et al., 2016). This pathway, characterised in yeast, is reported to consist of a cytosolic 
protein and two ER integral membrane proteins, and is mainly involved in targeting 
membrane proteins with internal TMDs that escape SRP. Its function overlaps with the SRP 
pathway, on the one hand, and with the GET pathway, on the other. In mammals, only a 
homologue of one of the ER proteins is present (SND2), and antibodies to this protein were 
provided by Richard Zimmermann (University of Saarland, Germany).  I silenced SND2 with 
four different oligonucleotide pairs, but obtained at most a non-statistically significant ~10% 
inhibition on b5-ER insertion in the silenced cells.  Reasoning that the lack of effect of SND2 
silencing could be due to compensation by the TRC40 pathway, I investigated the effect of 
silencing both pathways together; however, I found that SND2 silencing had very little effect 
over WRB silencing alone. Thus, I conclude that the SND pathway is not involved in b5 
targeting. 
Among the small molecule inhibitors that I tested in my assay, one, ES I, had a marked 
effect on b5-ER insertion, causing, at concentrations routinely used (10 - 100 μM), a 
reduction of up to 60% in the glycosylation of both the recombinant and the in vitro 
translated product. Quite strikingly, it was without effect on the TRC40-dependent 
substrate, Syb2, demonstrating that the process of glycosylation itself is not affected by ES 
I, and was equally effective on another TA substrate capable of unassisted insertion into 
protein-free liposomes (PTP1B, see Introduction). Thus, ES I seems to specifically target an 
ER targeting pathway used by spontaneously inserting TA proteins.  
As explained in the Introduction, ES I interferes with a number of processes occurring 
at the ER. It is best known as an ERAD inhibitor, which it inhibits by associating with p97. p97 
(also known as valosin-containing protein (VCP) is an AAA-ATPase (ATPase Associated with 
various cellular Activities) that plays a central role in the extraction of substrates from the 
ER lumen to the cytosol and their subsequent delivery to the proteasome. The association 
of ES I with p97 inhibits the activity of a p97-dependent deubiquitinating enzyme required 
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for completion of ERAD (Wang et al., 2008). To test whether p97 is involved in the response 
of b5 targeting, I applied a specific inhibitor of p97's ATPase activity, DeBQ.  The observation 
that this compound was without effect makes it unlikely that p97 inhibition underlies the 
effect of ES I on b5 and PTP1B insertion. 
In addition to its effect on ERAD, ES I also inhibits the Sec61 translocon (Cross et al., 
2009). Although it is known that Sec61 plays no role in the insertion of any TA protein into 
ER-derived microsomes in cell-free systems, we tested a possible involvement of Sec61 in 
our system, again comparing the effect of Sec61 downregulation on b5-ops and Syb2-ops 
glycosylation. Remarkably, I found that Sec61 silencing had an effect comparable to the one 
of WRB depletion on b5-ops, but not on Syb2-ops, glycosylation, indicating an unexpected 
role of the translocon in insertion of a spontaneously inserting TA protein, while again 
excluding its role in the insertion of a classical TRC40-dependent substrate (Syb2). The result 
further suggests that of ES I inhibition may be due to the effect of the inhibitor on the 
translocon.  Nevertheless, it should also be kept in mind that, due to the stability of the 
translocon, the silencing of Sec61 takes a full four days, and that I obtained efficient silencing 
with only one oligonucleotide pair.  At present, I cannot therefore exclude off-target effects 
of this siRNA or, more likely, effects secondary to Sec61 depletion. To investigate the 
relationship between the inhibitory effects of ES I and Sec61 downregulation, I am currently 
in the process of testing the effect of ES I on Sec61-silenced cells.  
Since my results uncovered two ER proteins, WRB and Sec61, as important players in 
b5-ER targeting/insertion, I asked what would happen if both these proteins were 
downregulated together. My reasoning was that, if each of them were operating in a distinct 
pathway, and if these two pathways represented the only available ones for b5-ER targeting, 
then concurrent blockage of both would result in increased reduction of b5-ER targeting, or 
even in potentiation of the inhibition. Instead, I found that cells downregulated for WRB and 
Sec61 were no less proficient in b5-ops glycosylation than the single silenced cells. There are 
two possible interpretations of this result: either TRC40/WRB and Sec61 are acting in the 
same pathway, so that regardless of whether each or both of them are silenced, the entire 
pathway is blocked; or the two pathways are different, but compensatory targeting 
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mechanisms come into play when both are downregulated. In either case, it is clear that 
pathways additional to the TRC40 and/or Sec61 pathway operate, as complete or near to 
complete inhibition of b5-ER targeting was never achieved in my system.  
 
Conclusions and Future Directions 
 
In the described research, I have used cyt b5 as model TA protein to investigate poorly 
understood post-translational targeting mechanisms.  Although my work has not uncovered 
all the pathways that guarantee robust targeting of this protein, it has generated important 
contributions to a problem important for cell biology, physiology, and pathology, as well. 
First, my work shows directly that the default destination for a spontaneously inserting 
ER-targeted TA protein is represented by the MOM. This result is in agreement with previous 
speculations based on indirect evidence. What features of the MOM are responsible for this 
is at present unclear. There are various approaches that could be undertaken to investigate 
this phenomenon, all rather risky and labor-intensive.  One might start with a purified MOM 
fraction (which is difficult to obtain in large quantities and of sufficient purity), and compare 
the kinetics of b5-ER insertion into the membranes of this fraction with the rather slow 
kinetics for insertion into ER microsomes. If, as hypothesized, the rate for insertion into the 
MOM is more rapid than into the ER, this faster insertion could be used as readout to 
evaluate the contribution of proteins and/or lipids of the MOM in the insertion process. 
Second, my work reveals that targeting of spontaneously inserting proteins to the ER is 
energy and chaperone-dependent, and that multiple pathways co-exist, which guarantee 
robust targeting of the substrates. Future research may identify the pathways that my 
research suggests do exist but that I have not yet identified. Again, this is a difficult task 
because of the redundancy of the pathways. Thus, an unbiased screening approach might 
fail to give any meaningful hit. One possible (labor-intensive) approach could be to use semi-
permeabilised, doubly silenced WRB/Sec61 cells in assays with RRL fractionated by various 
techniques, in an attempt to identify the cytosolic fraction that is active in the absence of 
the two ER receptors. 
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Interestingly, the additional pathways responsible for b5 targeting do not appear to be 
available to TA proteins with more hydrophobic TMDs, at least not in the system of semi-
intact cells that I used.  Indeed, interference with the TRC40 pathway essentially shut off 
Syb2-ops insertion, implying that it did not have access to the pathways that b5-ER was 
using. Conversely, treatments that affected b5-ER insertion (ES I treatment and Sec61 
downregulation) had no effect on the targeting of Syb2. Thus, different ER-targeted TA 
proteins rely on different targeting pathways. This situation contrasts with that of co-
translational protein insertion, which mainly relies on the SRP pathway. In conclusion, my 
results reveal redundant, but distinct pathways in post-translational targeting of different 
TA proteins to the ER, and open the way to the complete unraveling of the complexities of 
this process. 
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8. List of abbreviations 
 
  
AAA-ATPase ATPase associated with various cellular activities 
ATP Adenosine triphosphate 
b5 Cytochrome b5 
B5-ER ER-targeted form of b5 
B5-RR MOM-targeted form of b5 
BAM β-barrel assembly machinery 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
CAML Calcium modulating cyclophilin ligand 
CBB Coomassie brilliant blue 
CMV Cytomegalovirus 
COE Chloroplast outer envelope 
ConA Concanavalin A 
CPY Carboxypeptidase Y 
CTS Chloroplast targeting sequence 
DB Denaturation buffer 
DMEM Dulbecco's modified Eagle's medium 
EM Electron microscopy 
ER Endoplasmic reticulum  
ERAD ER associated degradation 
ES I Eeyarestatin I 
FBS Fetal bovine serum 
GDB Gelatin dilution buffer 
GET Guided entry of tail-anchored proteins 
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GS4B Glutathione-sepharose 4B resin 
GST Glutathione-S-transferase 
GTP Guanosine triphosphate 
HS High salt buffer 
IF Immunofluorescence 
IMP Integral membrane protein 
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
LB Luria Bertani 
mAb Monoclonal antibody 
MBP Maltose binding protein 
MFF Mitochondrial fission factor 
MIM Mitochondrial import machinery 
MOM Mitochondrial outer membrane 
mPTS Peroxisome targeting signal 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PDI Protein disufide isomerase 
PMP Peroxisomal membrane protein 
PTP1B Protein tyrosine phosphatase 1B 
RISC RNA-induced silencing complex 
RNAi RNA interference 
RNC Ribosome-nascent chain complex 
ROI Region of interest 
RRL Rabbit reticulocyte lysate 
RT Room temperature 
SAM Sorting and assembly machinery 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
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siRNA Small interference RNA 
SNARE Soluble NSF attachment receptor 
SND SRP-independent 
SR SRP receptor 
SRP Signal recognition particle 
SS Signal sequence 
Syb Synaptobrevin 
TA Tail-anchored 
TIM Translocase of the inner membrane  
TMD Transmembrane domain 
TOM Translocase of the outer membrane 
TPR Tetratricopeptide repeat 
TRAM Translocating-chain associating membrane 
TRAP Translocon associated protein 
TRC Transmembrane recognition complex 
UBL Ubiquitin-like domain 
VCP Valosin-containing protein 
WB Western blot 
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